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Endothelin-1 Polymorphisms and Endothelin-1 Cerebrospinal Fluid Protein Expression 
and their Relationships to Cerebral Vasospasm and Long Term Outcomes in 
Individuals Following Aneurysmal Subarachnoid Hemorrhage 
Matthew J Gallek, RN, PhD 
University of Pittsburgh, 2008
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease that affects approximately 
25,000 people a year in the United States.  Cerebral vasospasm (CV) is a common complication 
after SAH.  In addition SAH patients have poor long term outcomes, with 40-50% of patients 
suffering severe neurological disabilities.   The most vital step in preventing CV and poor long 
term outcomes is identifying patients at increased risk of these poor outcomes.  Endothelin-1 
(ET-1) is a potent vasoconstrictor that may play a role in the pathogenesis of CV.  Genetic 
variation within the ET-1 gene may also account for some of the variance observed in the 
outcomes of SAH patients.  The purpose of this study was to examine the effects of ET-1 CSF 
protein expression, and ET-1 SNPs on CV in individuals suffering from SAH.  In addition, the 
relationship between long-term outcomes, ET-1 SNPs, and ET-1 CSF protein expression in 
patients with SAH was evaluated.  This study included individuals ages 18-75 with a diagnosis 
of aneurysmal SAH.  CSF samples were collected from a drainage catheter.  ET-1 levels CSF 
were measured using chemiluminescent ELISA kits.  Genotyping was performed using 
TaqMan® allele discrimination assays.  Individuals with CV had average CSF ET-1 elimination 
rates (7.94±6.47pg/hr) that were increased in the 72 hours before angiography when compared to 
individuals without CV (4.35±3.02 pg/hr).  Of the 9 ET-1 SNP’s investigated, the variant allele 
of 1 SNP (rs2070699) was associated with the development of CV.  The odds ratio of the 
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heterozygous genotype compared to the homozygous wild-type genotype was 2.970 with a 95% 
confidence interval of 0.998 to 8.836.  The odds ratio for the homozygous variant genotype 
compared to the homozygous wild-type genotype was 8.356 with a 95% confidence interval of 
2.032 to 34.371.  No relationships were found between ET-1 SNPs and long-term outcomes.  In 
addition a predictive model with CSF ET-1 levels and ET-1 SNPs had no significant 
relationships with long-term outcomes.  This study supports the use of ET-1 levels and ET-1 
genotypes as predictors of CV, but not of long term outcomes.   
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1.0  PROPOSAL INTRODUCTION 
There are approximately 25,000 cases of subarachnoid hemorrhage (SAH) in the United States 
each year (Longstreth, Koepsell, Yerby, & van Belle, 1985) most of which occur in women at an 
average age of 55 years old (Sobey & Faraci, 1998).  Ninety five percent of cases of spontaneous 
SAH result from ruptured cerebral aneurysms (aSAH) (Sobey & Faraci, 1998).  Patients who 
survive the initial hemorrhage and subsequent surgical or radiological intervention then face the 
potential of developing cerebral vasospasm (CV).  Cerebral vasospasm can result in diminished 
blood flow to cerebral tissue and subsequent ischemia and is the most common cause of 
mortality and morbidity after aSAH, occurring  in 40-60% of individuals recovering from aSAH 
(Schievink, Schaid, Michels, & Piepgras, 1995).  The most vital step in preventing CV is 
identifying patients at increased risk of CV.  Once these patients are identified, closer monitoring 
and more aggressive interventions may be implemented.  While numerous causal factors of CV 
have been investigated (Cohen, Vanhoutte, Cohen, & Vanhoutte, 1995; Hatake et al., 1992; 
Kasuya et al., 1995; P. Kim, Schini, Sundt, & Vanhoutte, 1992; Onoue et al., 1995; Sobey, 
Heistad, & Faraci, 1996; Yamamoto et al., 1997), the search for a single factor has been 
disappointing; a complex multifactorial etiology is most probable (Hamann & Schimrigk, 1995).   
Researchers have suggested that endothelin-1 (ET-1), a potent vasoconstrictor produced 
by the endothelial cells of the vasculature (H. Suzuki, Sato, Suzuki, Oka et al., 1990), may play a 
role in the etiology of CV (Mascia, Fedorko, Stewart, Mohamed, terBrugge, Ranieri, Wallace et 
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al., 2001; Seifert, Loffler, Zimmermann, Roux, & Stolke, 1995; Yamaji et al., 1990; 
Yanagisawa, Kurihara, Kimura, Tomobe, Kobayashi, Mitsui, Yazaki, Goto, Masaki et al., 1988).  
A functional polymorphism (Lys198Asn) of the gene encoding preproendothelin-1 has shown 
differences in vasculature reactivity (Iglarz et al., 2002).  Preproendothlein-1 is a precursor to 
ET-1; therefore a polymorphism that changes the preproendothlin-1 protein had a direct affect on 
the ET-1 protein.  The difference in vasculature reactivity caused by this polymorphism may 
have an effect on the presence of or severity of CV thereby influencing long-term outcomes.  
Along with this functional polymorphism, other polymorphisms in the gene for ET-1 may 
influence CV and long-term outcomes.  By investigating the tagging single nucleotide 
polymorphisms (tSNP’s) of the ET-1 gene all of the genetic variation within the ET-1 gene will 
be evaluated in this analysis.  Few studies have investigated genetic influences on development 
of CV, yet genetic polymorphisms that effect ET-1 may have an influence on CV after aSAH 
and therefore influence long-term outcomes. 
1.1 PURPOSE 
The purpose of this study was to examine the effects of ET-1 cerebrospinal fluid (CSF) protein 
expression, tSNP’s for ET-1 and Lys198Asn polymorphism on CV in individuals suffering from 
aSAH.  In addition, the relationship between long term outcomes, ET-1 polymorphisms, and ET-
1 CSF protein expression in patients with aSAH was evaluated.  
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1.2 SPECIFIC AIMS 
The specific aims were: 
1) Describe the distribution of Lys198Asn and tSNP of the ET-1 gene in individuals 
recovering from aSAH.   
2) Describe the relationship between the ET-1 polymorphisms and CV after aSAH. 
3) Describe the relationship between the ET-1 polymorphisms and long term outcomes 
after aSAH. 
4) Describe the CSF ET-1 protein expression for the 3 days prior to CV measurement. 
5) Describe the CSF ET-1 protein expression, in relation to Lys198Asn and tSNP’s, of 
individuals with and without CV over time for the first 14 days after aSAH. 
6) Describe the CSF ET-1 protein expression, in relation to Lys198Asn and tSNP’s, of 
individuals with and without CV over time for the 3 days prior to CV measurement. 
7) Describe the CSF ET-1 protein expression over the first 14 days after aSAH, in 
association with Lys198Asn and tSNP’s, and its potential relationship with long term 
outcomes.  
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1.3 RESEARCH FRAMEWORK 
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Figure 1: Diagram of research framework used for this study. 
1.4 BACKGROUND AND SIGNIFICANCE 
Subarachnoid hemorrhage occurs in approximately 1 out of 10,000 people in the United States 
each year(Longstreth et al., 1985) and is associated with a fatality rate of 30-50% (Sobey & 
Faraci, 1998).  Those that survive the initial hemorrhage have a 40-50% chance of suffering 
severe long term neurological disabilities (Sobey & Faraci, 1998).  A SAH is a type of 
hemorrhagic stroke that occurs when blood enters the subarachnoid space around the brain.  The 
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most common cause of SAH is aneurysmal rupture of one of the major arteries of the brain 
(Longstreth et al., 1985).   Other less common causes of SAH include rupture of an arteriovenous 
malformation and trauma.  These causes of SAH will not be investigated in this study due to the 
fact that CV is not a common complication for these patients.    
1.4.1 Cerebral Aneurysms 
Cerebral aneurysms are abnormal focal out-pouchings of cerebral arteries.  Autopsy studies have 
shown that cerebral aneurysms have a prevalence in the adult population between 1 and 5 
percent (Wiebers et al., 2003).  It has been estimated that 50 to 80 percent of all aneurysms do 
not rupture (Connolly & Solomon, 2004).  Risk factors associated with cerebral aneurysm 
formation include being female, increased age, hypertension, and cigarette smoking (Schievink, 
1997). Conditions associated with cerebral aneurysms include autosomal dominant polycystic 
kidney disease, firbromuscular dysplasia, Marfan’s syndrome, and Ehlers-Danlos syndrome type 
IV (Vega, Kwoon, & Lavine, 2002).  Numerous studies have found a strong relationship between 
cerebral aneurysm formation and familial relationships (De Braekeleer et al., 1996; Kassell et al., 
1985; Kojima et al., 1998; Norrgard et al., 1987; Ronkainen et al., 1997; Ronkainen et al., 1993) 
suggesting there is a genetic predisposition to aneurysm development.   
Little is known about the cause of intracranial aneurysms or the process by which they 
form, grow, and rupture.  The most common histological finding is a decrease in the tunica 
media.  The tunica media is the middle muscular layer of the artery.  This decrease in the tunica 
media causes structural defects that most often occur at arterial branch points in the subarachnoid 
space at the base of the brain (Schievink, 1997).   
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1.4.2 Cerebral Vasospasm  
The morbidity and mortality rate of aSAH has decreased little over the past 40 years (Solenski, 
Haley, Kassell, Kongable, Germanson, Truskowski, Torner et al., 1995).  Surgical methods have 
been developed improving survival rates of the initial injury.  While surgery decreased the risk of 
aneurysmal rebleed, the frequency of secondary injuries became evident and survival from aSAH 
did not improve.  In great part due to the frequency of CV (Solenski, Haley, Kassell, Kongable, 
Germanson, Truskowski, Torner et al., 1995).  Cerebral vasospasm can lead to delayed cerebral 
ischemia, furthering neurological damage, and often leads to ischemic stroke.  Worse outcomes 
have been associated with the presence of CV (Goto & Yamagata, 2006; Ratsep & Asser, 2001).  
Cerebral vasospasm has been correlated with a 1.5 to 3 fold increase in mortality in the first 2 
weeks after aSAH and occurs in 30-70% of all patients with  aSAH (Treggiari-Venzi, Suter, 
Romand et al., 2001).  Cerebral vasospasm occurs with a peak incidence 3 to 12 days after the 
initial aSAH (Newell, Eskridge, Mayberg, Grady, Winn et al., 1989).  Angiographic CV, a 
decrease of the lumen of the cerebral vasculature of >25% as measured using cerebral 
angiogram, occurs in up to 70% of patients with aSAH (Dorsch, 2002). If the angiographic CV is 
severe enough to cause ischemia the patient will develop symptomatic CV (vessel narrowing on 
angiography followed by changes in clinical neurological status) which affects nearly one third 
of the patients.  Without appropriate treatment CV can result in death in 30% and permanent 
disability in 34% of patients (Dorsch, 2002).  There are few accurate predictors of CV including 
amount and distribution of blood on CT scan (categorized by Fisher grade), age, hypertension, 
cigarette smoking, and cocaine use (Conway & Tamargo, 2001; Qureshi et al., 2001).  However, 
these risk factors do not accurately predict the occurrence of CV.  The neuroscience nurse can 
play a critical role in preventing ischemic damage secondary to CV.  Frequent neurological 
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assessment performed by nurses in the critical care setting often identifies the development of 
symptomatic CV (Kosty, 2005).  Further, nursing management of patients recovering from 
aSAH is aimed at preventing secondary brain injury due to CV (Littlejohns & Bader, 2005).  
Genetic susceptibility may play a role in better identifying patients at a high risk of CV.  Once 
these risks are identified, closer monitoring and more aggressive interventions may be 
considered only for those at increased risk.   
The underlying pathophysiologic mechanism for CV remains unknown.  Researchers 
have reported that the breakdown of blood in the subarachnoid space corresponds to the 
occurrence of CV such that increased blood in the subarachnoid space is associated with a 
greater development and severity of CV (Treggiari-Venzi, Suter, Romand et al., 2001).  The 
physiological phenomena supporting this association, however, are unclear.  One potential 
mechanism for development of CV after aSAH involves ET-1.  
1.4.3 Endothelin-1 (ET-1)   
Endothelin-1 is a long lasting vasoconstrictor that is produced by the endothelial cells of the 
vasculature (Petzold, Einhaupl, Dirnagl, & Dreier, 2003; H. Suzuki, Sato, Suzuki, Oka et al., 
1990).  The actions of ET-1 are balanced by the actions of nitric oxide in normal physiology and 
account for normal vascular tone.  Nitric oxide is a short acting but powerful vasodilator 
produced by nitric oxide synthases produced by endothelial  and other cells (Sobey & Faraci, 
1998).  Nitric Oxide also inhibits the synthesis of ET-1 (Boulanger & Luscher, 1990).  When 
ET-1 is released it binds to the ETA receptors on the vasculature smooth muscle.  The ETA 
receptor is coupled with a G-protein which releases a second messenger, inositol triphosphate 
(IP3).  The release of the second messenger stimulates the sarcoplasmic reticulum to release 
 18 
calcium eliciting vasoconstriction (Salom, Torregrosa, & Alborch, 1995; Zimmermann & Seifert, 
1998). In addition ET-1 also increases calcium entry through voltage gated calcium channels 
(Weir, 1995).  Recent animal studies have shown that ET-1 concentration is directly related to 
ischemia caused by vasoconstriction of the cerebral vasculature (C. Y. Kim et al., 2003; Petzold, 
Einhaupl, Dirnagl, Dreier et al., 2003).  Petzold and associates investigated cerebral blood flow 
on rats using a laser-Doppler.  Rats had a cranial window surgically implanted so that ET-1 and 
other chemicals could be infused directly on the vasculature of the brain.  The infusing of ET-1 
caused a decrease in cerebral blood flow.  When ET-1 was combined with oxyhemoglobin the 
cerebral blood flow further decreased.   
Suzuki and associate reported increased levels of ET-1 in CSF of aSAH patients (H. 
Suzuki, Sato, Suzuki, Takekoshi et al., 1990).  Recent studies showed that CSF ET-1 levels are 
associated with the development of CV after aSAH (Kessler, Pacheco, Lozzi, de Araujo, Onishi 
et al., 2005), thus supporting the role of ET-1 in the pathogenesis of CV.  Kessler and associates 
collected CSF samples from 30 patients diagnosed with aSAH.  The collections of these samples 
varied and were all collected within the first 23 days after aneurysm rupture.  They also collected 
CSF samples from 10 healthy subjects.  There were significantly higher ET-1 CSF 
concentrations in the aSAH group when compared to the control group. This group found an 
increase in ET-1 CSF concentrations until the 6th day with a progressive decrease afterward, this 
was similar to what Suzuki and associates (1990) found.  Finally, Kessler and associates found 
significantly higher ET-1 CSF concentrations in subjects with CV compared to subjects without 
CV.   
What remains unclear is the temporal relationship of ET-1 CSF levels to CV.  Mascia et 
al. investigated the temporal relationship between ET-1 and CV(Mascia, Fedorko, Stewart, 
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Mohamed, terBrugge, Ranieri, & Wallace, 2001).  Mascia and associates collected CSF samples 
from 20 subjects diagnosed with aSAH on day 1, day 4, and day 7 after aneurysm rupture.  The 
subjects then had an angiography performed on day 7 to measure CV.  These subjects were then 
divided into 4 groups: Clinical CV, Angiographic CV, no CV, and poor neurological condition 
without CV.  When groups were compared on day 1 and day 4 there were no significant 
differences.  However, on day 7 the clinical CV and poor neurological condition groups had 
significantly higher ET-1 concentrations when compared to the no CV and angiographic CV 
groups.  Because there were no differences between groups on day 1 and 4 the authors believe 
that ET-1 may not be an accurate predictor of CV.  The authors expected an increase in ET-1 
concentrations to occur before the actual CV occurred.  These findings led the authors to believe 
that ET-1 concentration may be related to the degree of neuronal damage rather than CV.  
However, the collection of CSF may not have occurred frequently enough to show an increase in 
concentration before the occurrence of CV.   
1.4.4 Preproendothelin-1 Polymorphism  
One genetic polymorphism associated with variation in vascular reactivity is a polymorphism of 
preproendothelin-1 (RS5370) (Iglarz et al., 2002).    Endothelin-1 is derived from 
preproendothelin-1.  The preproendothelin-1 gene is located on chromosome 6.  The 
polymorphism of the gene coding for preproendothelin-1  is described as a G-to-T transversion at 
position 5665 affecting the 61st nucleotide of exon 5, which predicts a Lys/Asn change at codon 
198 (Iglarz et al., 2002).  A G- to-T transversion is a point mutation in which a purine (G-
Gaunine) is replaced by a pyrimidine (T-Thymine) in the DNA sequence.  This particular change 
in the preproendothelin-1 gene changes the peptide sequence in the mature protein.  In this case a 
 20 
lysine (Lys) is replaced by an asparagine (Asn), leading to a structurally and functionally 
different preproendothelin-1 isoform, which leads to a functionally different ET-1 isoform.  The 
variant ET-1 isoform (coded for by the T allele) is associated with an increased responsiveness in 
human mammary artery ring segments (Iglarz et al., 2002).  Human mammary artery was 
removed from patients during coronary artery bypass surgery and later exposed to different 
concentrations of ET-1.  It took lower concentrations of ET-1 to cause contraction in vessels of 
individuals with a T allele.  The ET-1 that was exposed to the artery segments was an ET-1 that 
was not polymorphism specific.  It was ET-1 purchased from a pharmaceutical lab.  Therefore, it 
is not clear if the artery segments had different responsiveness due to the ET-1 polymorphism 
directly, or if the polymorphism caused a change in the ET-1 receptors that influenced 
responsiveness.  This is the first study to show a difference in vessel reactivity due to the 
preproET-1 polymorphism.  This increased vessel reactivity may increase the risk of CV in 
patients recovering from aSAH.  Ultimately affecting long term outcomes in these patients.   
 Lys198Asn has been investigated in other diseases and phenotypes.  Significant 
associations with Lys198Asn have been found in the following phenotypes: urinary albumin 
excretion (Pinto-Sietsma et al., 2003), glomerular filtration rate (Pinto-Sietsma et al., 2003) and 
blood pressure in women (Funalot et al., 2004).   In all cases the functional relevance of the 
associations are not clear.  Non-significant associations have been found in the following 
diseases or phenotypes: blood pressure (Dong, Wang, Zhu, Treiber, & Snieder, 2004), left 
ventricular mass index(Dong et al., 2004), ET-1 level in vitro(Tanaka, Kamide, Takiuchi, 
Kawano, & Miyata, 2004), and cerebral small vessel disease(Gormley, Bevan, Hassan, & 
Markus, 2005).  The differences in association between Lsy198Asn and blood pressure may be 
due to the methods and populations used by the two studies.  Funalot and associates (2004) 
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found an association between Lys198ASN and systolic and mean blood pressure in older (Mean 
age 65) women.  While Dong and associates (2004) investigated this association in a younger 
population (Mean age 12) over a 15 year period.   
1.4.5 Endothelin-1 System Tagging SNP’s   
The majority of genetic variation among people can be characterized by single nucleotide 
polymorphisms (SNP).  These polymorphisms are mutations that occur at single nucleotide 
positions.  It has been estimated that there are about 7 million common SNP’s in the human 
genome (Botstein & Risch, 2003; Kruglyak & Nickerson, 2001).  There may be hundreds of 
SNP’s associated with an individual gene such as the ET-1 gene.  Genotyping each of these 
numerous SNP’s is time consuming and not cost effective.  Tagging SNP’s allow researchers to 
genotype a single nucleotide polymorphism that represents a larger region of the gene. Therefore 
it is possible to identify genetic variation without genotyping every SNP in a chromosomal 
region. 
By exploring tagging SNP’s, the proposed study examined how genetic differences found 
in the ET-1 gene, may be used as an indicator of which patients are at a higher risk of vasospasm 
and subsequent worse outcomes.  By exploring all of the tagging SNP’s of ET-1 all genetic 
variance can be accounted for in the ET-1 gene, including potentially functional polymorphisms.  
At the present time there are no studies published that investigate ET-1 tSNP’s or ET-1 
functional SNP’s and their association with CV, or outcomes following aSAH.  The novelty of 
this study is that it will explore gene expression (ET-1 levels) in the CSF of individuals with and 
without CV after SAH in light of genetic polymorphisms.   
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This study will advance nursing research in human genetics, as well as potentially affect 
nursing interventions after aSAH by helping to identify and focus resources on patients at higher 
risk of CV and poor long term outcomes.  The results of this study will also promote the 
integration of nursing process into the delivery of genomics-based healthcare services.  
Additionally, this study may lead to improvement in cost effectiveness. The patients that are at a 
lower risk of CV may be able to have less costly tests, interventions, and a shorter ICU or 
hospital stay thereby decreasing the overall cost of the hospital stay.  Finally, the results of this 
study will add to the literature on mechanism of CV and encourage development of interventions 
aimed at decreasing CV after aSAH and improving long term outcomes. 
1.5 PRELIMINARY STUDIES 
1.5.1 Preliminary Study #1  
Preproendothelin-1 Polymorphism (Lys198Asn) and its Relationship to Long Term Outcomes 
after Subarachnoid Hemorrhage: A Pilot Study 
Purpose: The purpose of this study was to examine the Lys198Asn and its relationship to 
long-term outcomes after aSAH.   
Methods:  
• aSAH patients 
– Age 21-75 
– Fisher Grade >1 
– No history of preexisting neurological diseases 
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– DNA samples were collected as part of a parent study 
• Genotyping  
– An ABI Prism® 7000 Sequence Detection System was used. 
–  TaqMan® assays were used for allelic discrimination. 
• Long Term Outcomes 
– Modified Rankin Scale 
– Glasgow Outcome Score 
– Collected at 3 months and 6 months after aneurysm rupture 
Results: Genotype data collected on 228 subjects.  The frequency of genotypes associated 
with the Lys198Asn included:  homozygous GG wild type n=150 (66%), heterozygous GT n=65 
(28%), and homozygous TT n=13(6%).  The distribution of alleles within this study had a higher 
percentage of variant alleles than would be expected when compared to the normal population.  
Of the 228 that were genotyped 3 month outcome data was collected on 187 (72%) individuals 
41 had missing 3 month outcomes.  There were 168 (74%) individuals with 6 month outcomes 
data and 60 with missing 6 month outcomes data.   
Conclusions: There were no significant relationships found between Lys198Asn and long 
term outcomes.   
1.5.2 Preliminary Study #2  
 
Preproendothelin-1 Polymorphism (Lys198Asn) and its Relationship to Cerebral Vasospasm 
after Subarachnoid Hemorrhage: A Pilot Study. 
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Purpose: The purpose of this study is to examine different genotypes of the Lys198Asn in 
individuals with and without CV after aSAH.   
Methods: 
• aSAH patients 
– Age 21-75 
– Fisher Grade >1 
– No history of preexisting neurological diseases 
– DNA samples were collected as part of a parent study 
• Genotyping  
– An ABI Prism® 7000 Sequence Detection System was used. 
–  TaqMan® assays were used for allelic discrimination. 
• CV determination 
– Angiography performed day 3 to day 14 
– Angiography coded by Neurosurgeon 
Results: Genotype data was collected on 138 subjects.   The frequency of genotypes for 
Lys198Asn included:  homozygous GG wild type n=96 (70%), heterozygous GT n=34 (24%), 
and homozygous TT n=8 (6%).  The distribution of alleles within this study had a higher 
percentage of variant alleles than would be expected when compared to the normal population.  
Of the 159 subjects 76 (48%) suffered from CV. 
Conclusion:  There were no significant relationships found between the preproendothelin-
1 polymorphism and CV.   
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1.5.3 Additional Experiences 
In addition to the two formal studies listed above, I was able to have adequate funds that allowed 
me to genotype 8 tSNPs of endothelin-1.  One tSNP was associated with CV and three of the 
tSNP’s are associated with long term outcomes.  This data were presented at an international 
conference in February of 2008. 
When I began the doctoral program I was a bedside nurse on a 10 bed neurovascular 
ICU.  My experiences there included working with patients with large ischemic and hemorrhagic 
strokes.  In addition to this I took care of aSAH patients and was able to observe these patients in 
a clinical setting.  
Since that time I have become a graduate student researcher (GSR) on a grant 
investigated aSAH patients.  Experiences include:  
• Consenting patients and their families. 
• Collecting urine, blood, and CSF samples and processing them for later 
protein analysis. 
• Collection of demographic and clinical data. 
• Endothelin-1, Nitric Oxide, and 20-HETE analysis of CSF and Plasma. 
• Database Management. 
• Performance of Transcranial Doppler.  
• Data Analysis 
• Writing for scientific journals 
• Presentation of research findings 
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1.6 RESEARCH DESIGN AND METHODS 
1.6.1 Design   
This study was a longitudinal descriptive correlational study. Demographic, angiographic, 
outcome data, blood and CSF samples were previously collected as part of two ongoing research 
studies (R01-NR04339, PI Dr. Leslie Hoffman and an unfunded study, PI Dr. Amin Kassam) 
being conducted at the University of Pittsburgh School of Nursing.  The subjects from these 
parent studies consented for the use of all data, their genetic material, and biological samples in 
further studies of aSAH. 
1.6.2 Clinical Setting  
 Patients were admitted to the Neurovascular intensive care unit (NICU) at the University of 
Pittsburgh Medical Center (UPMC), Pittsburgh Pennsylvania.  This is a 20 bed intensive care 
unit that specializes in the care of individuals with acute neurological injuries.   
1.6.3 Sample 
The population presenting to the University of Pittsburgh Medical Center for treatment of aSAH 
is approximately 65% women and 9% African American, which is consistent with the general 
SAH population in the Pittsburgh area.  Patients were enrolled in the parent studies within 48 
hours of admission.  Informed consent was obtained based on an Institutional Review Board 
accepted protocol. 
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The inclusion criteria for the parent studies were as follows:  1) 21 to 75 years of age.  2)  
diagnosis of an aSAH confirmed by CT scan (Fisher grade ≥ 2) and angiogram.  Exclusion 
criteria include:  1) SAH due to trauma, mycotic aneurysm rupture, arterial-venous malformation 
rupture, or from an unknown source and 2) pre-existing neurological disease or injury.  The 
inclusion criteria for this study included the criteria above with one additional criterion: a DNA 
sample must be available for genotyping.  There were no additional exclusion criteria for this 
study when compared to the parent study. 
Adults 21 and older were chosen because the incidence of aSAH in children is <0.001% 
(Anderson, Jamrozik, Broadhurst, & Stewart-Wynne, 1994).  To prevent the influence of 
comorbidities on our sample the maximum age for the study was 75 years.  Patients with a 
diagnosis of aSAH were graded as a Fisher grade 2 or greater.  Fisher grade 0 is a patient without 
a ruptured aneurysm, and a Fisher grade 1 has no blood present on a CT scan.  Since blood load 
is associated with CV, patients with increased risk of CV are graded 2 and above.  Patients with 
SAH from non-aneurysmal sources have a decreased risk of CV, receive different medical 
treatment, and have a different course of recovery and therefore will not be included in this 
study.  To avoid confounding our results, patients were also excluded from this study if they 
have a pre-existing neurological disease or injury. 
1.6.4 Recruitment   
Subjects were recruited as part of two ongoing research studies (R01-NR04339, PI Dr. Leslie 
Hoffman and an unfunded study, PI Dr. Amin Kassam) being conducted at the University of 
Pittsburgh School of Nursing.  The parent study personnel would make daily rounds in the 
NVICU with the nursing staff.  Potential patients with a diagnosis of SAH were reviewed for 
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parent study eligibility.  Once it was established that the patient was eligible, the bedside nurse 
would ask the permission of the patient or family to be approached by the study personnel.  With 
the verbal permission of the family or patient the project personnel would present the study and 
obtain informed consent.  Both of the parent studies were approved by the institutional review 
board.  The subjects from these parent studies consented for the use of all data, their genetic 
material, and biological samples in further studies of aSAH.  Therefore, there is no additional 
recruitment for this proposed study. 
1.6.5 Standard of Care  
All individuals presenting to the University of Pittsburgh Medical Center (UPMC) 
Presbyterian/Shadyside were admitted to the Neurovascular ICU (NVICU).  Upon admission all 
patients received a computed tomography (CT) scan of the head to confirm SAH.  Fisher Grade 
and Hunt and Hess grade were assigned by a neurosurgeon upon admission.  Cerebral 
Angiography was then performed to identify the source of the SAH.  Upon confirmation of 
aSAH the attending neurosurgeon decided if the aneurysm would be embolized using platinum 
coils or clipped surgically.  All patients receive central venous catheters.  Patient monitoring 
included central venous pressure, arterial blood pressure, pulse oximetry, respiratory rate, cardiac 
rate, and cardiac rhythm. An extraventricular drain (EVD) or lumber drain was placed if it was 
necessary to treat for hydrocephalus or increased intracranial pressure.  All EVD’s monitored 
intracrainial pressure (ICP) continuously.  Patients were intubated and ventilated as needed.  
Temperature was monitored every two hours by oral or rectal measurement.  Complete 
neurological exams were performed by registered nurses every two hours.  All patients receive 
triple ‘H’ therapy.  Triple ‘H’ therapy consists of hypertension, which is accomplished by 
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increasing the patient’s blood pressure to higher than normal values.  The second ‘H’ is 
hypervolemia.  The patient receives large amounts of IV fluids, which also helps to keep the 
blood pressure elevated and the cerebral vessels open.  The goal for hypervolemia is a CVP 
greater than 8 mmHg.  The final ‘H’ is hemodilution.  By receiving large amounts of fluids the 
patient’s blood is hemodiluted, which allows the blood to flow easier through the cerebral 
vasculature. The goal for hemodilution is a hematocrit of 30% to 40%.  Sixty mg of nimodipine 
(Nimotop) was given every 4 hours for the first 21 days after aneurysm rupture.  Nimotipine is a 
calcium channel blocker that is the only FDA approved medication for the prevention of CV.  
Recently, magnesium sulfate has been show to help prevent cerebral vasospasm (Chia, Hughes, 
& Morgan, 2002).  Therefore all patients receive 12 grams a day of magnesium sulfate by 
continuous infusing for the first 12 days.   In the event of clinical or angiographic vasospasm, 
patients are treated by increasing their systolic blood pressure to a minimum of 180 mmHg.  This 
is accomplished by infusion of a vasopressor.  Norepinephrine is the most common vasopressor 
used at UPMC.  Intra-arterial papaverine and balloon angioplasty are endovascular treatments 
that may be used at UPMC at the discretion of the attending neurosurgeon.  Anti-convulsants 
were administered for all patients.  Sedatives were administered as needed for patient agitation.    
1.6.6 Research Setting 
1.6.6.1 Genetic Laboratory 
All additional genetic analysis occurred at the University of Pittsburgh School of Nursing.  Dr. 
Yvette Conley has a molecular genetics laboratory located in the Victoria Building at the 
University of Pittsburgh School of Nursing.  This laboratory is a 3200 square foot facility 
divided into three sections, a culture room facility, a pre-PCR room and a post-PCR/equipment 
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room.  Major equipment available in the laboratory include an ABI377 automated 
sequencer/genotyper with all of the necessary computer equipment and software for analysis of 
data, the WAVE® Nucleic Acid Fragment Analysis System from Transgenomic to perform 
dHPLC, an ABI7000 for TaqMan® real time PCR and allele discrimination assays, a Turner 
Designs Luminometer, various horizontal/vertical electrophoresis units and power supplies, 
several SSCP apparatus, a gel documentation system, centrifuges, a spectrophotometer, a cold 
room for DNA storage, ultra-low freezers, culture room equipment, and several 96-well thermal 
cyclers.  The laboratory is completely OSHA compliant and is up to date for all required 
inspections.  Three technicians with advanced degrees are employed full time in the laboratory. 
1.6.6.2 Specimen Laboratory  
In addition to the genetics laboratory, Dr Poloyac has a biological specimen laboratory at the 
University of Pittsburgh School of Pharmacy.  The research in Dr. Poloyac's laboratory utilizes 
contemporary methods of analytical chemistry coupled with molecular biology in the pursuit of 
generating new knowledge about the pathogenesis of neurotraumatic disease. The laboratory is 
completely OSHA compliant and is up to date for all required inspections. Two technicians with 
advanced degrees are employed full time in the laboratory. 
1.6.7 Procedures for Data Collection 
Demographic data was collected from the parent study.  Gender, race, and age were collected 
from medical. Data collection sheets were electronically transmitted directly into an automated 
data entry and verification system (Teleform). Data was stored in a locked office of the project 
personnel of one of the parent studies.  Data that used for this study was extracted from the 
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databases of the parent study by one of the study personnel.  All data that is needed for this study 
was requested from the study personnel in writing.  A new database for this study was 
constructed using all of the requested data from the parent studies.  In order to assure subject 
confidentiality, all identifiers were removed from the data.  A non-identifying study number was 
given to link the parent study data and biological samples for this study. 
1.6.8 DNA Specimens  
 Subjects had 10cc of whole blood drawn on day one of enrollment into the parent studies.  The 
tube of blood was delivered to Dr. Conley’s laboratory with no personal identifiers, only the 
study participant’s identification number, date of sample collection, and time of sample 
collection.  The sample was logged in and centrifuged, the white cells removed, and DNA 
extracted from the white cells using a simple salting out procedure (Miller, Dykes, & Polesky).  
All DNA is stored in 1X TE buffer at 4°C.   
1.6.9  Genotyping  
Genotyping was performed as follows: An ABI Prism® 7000 Sequence Detection System was 
used to conduct allele discrimination assays using TaqMan® assays.  This is a highly automated, 
high throughput genotyping method for SNPs.  Primers flank each polymorphism and PCR is 
conducted using subject DNA.  The main difference between TaqMan® PCR and traditional 
PCR is the use of a probe that is labeled with a reporter and a quencher dye that recognizes a 
specific allele of a SNP.  Each allele of a SNP has its own probe with its own reporter dye.  If the 
subject’s DNA is homozygous for one allele of the SNP, only the probe for that allele will 
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hybridize and only the reporter dye for that allele will be liberated and measured by the ABI 
Prism® 7000 Sequence Detection System.  A heterozygote will have both probes hybridize and 
both reporter dyes measured.  Using this method, each SNP can be genotyped accurately and 
quickly. For the currently chosen SNP, TaqMan® assays on demand are already available 
through ABI.  200ng of subject DNA was utilized for this assay and more than enough DNA was 
available to conduct this assay. 
Tagging SNP’s of ET-1 and Lys198Asn were classified into one of three genotypes.  
These genotypes were homozygous for the wild type, homozygous for the variant, or 
heterozygous.   
1.6.10 Cerebrospinal Fluid (CSF) Specimens 
Cerebrospinal fluid (CSF) specimens were obtained twice daily from either extraventricular 
drains (EVD) or via lumbar drains (LDs). These drains were placed as part of medical care for 
the treatment of aSAH.  The drains were placed using sterile techniques by trained 
neurosurgeons. EVDs were placed into the lateral ventricle and the lumbar drains were placed 
into the subarachnoid space of the lumbar spine between L-3 and L-5.  To obtain the fresh 
samples, specimens were collected using sterile technique directly from the drainage catheter at 
the site closest to the patient as per institutional policy and then immediately frozen in cryogenic 
vials to –20oC in a laboratory across from the clinical unit. At the end of 14 days when all 
collections were completed the specimens were stored in –80oC freezers in the School of 
Nursing until analysis.   
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1.6.11 ET-1 CSF Analysis 
The CSF samples were assayed for ET-1 using the ELISA kit (Human Endothelin-1) from R&D 
Systems (Minneapolis, MN) and according to manufacturer’s instructions.  This assay employs 
the quantitative sandwich enzyme immunoassay technique with chemiluminesent detection.  The 
standard curve was modified from the R&D recommendations to include 0.195, 0.39, 0.78, 1.56, 
3.13, 6.25, & 12.5 pg/ml standards.  Precision and accuracy of the modified standard curve range 
was evaluated and the coefficient of variation was less than 15 % over the range of standards 
utilized.  The intra-assay and inter-assay coefficients of variation were 3.4% and 8.9% 
respectively.  This range of standards was used to cover the range of concentrations observed in 
the CSF of SAH patients.  A microplate luminometer (Model # 1420-012 Victor-Wallac, 
Finland) is used to measure the intensity of the light emitted.  Many of the CSF samples have 
been analyzed as part of the parent study.  The analyses have been performed by the laboratory 
technicians of Dr. Poloyac’s laboratory or by me.   
1.6.12 Cerebral Vasospasm 
Cerebral vasospasm was diagnosed by identification of narrowing of cerebral vessels as 
documented on four vessel cerebral angiography.  Cerebral angiography was conducted as 
standard of care on admission, as postoperative follow-up, or in the event of a neurological 
deterioration.  The angiographic studies were interpreted and graded by neuro-radiologist and 
neurosurgeons at UPMC for evidence and degree of vasospasm. Coding of CV measured by 
cerebral angiography for our group has an inter-rater reliability kappa of 0.81.  The degree of 
vasospasm was represented as the percentage of narrowing in the cerebral vessels as follows: 
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none to minimal, 0 to 25% narrowing; moderate, 26-75% narrowing; severe, 76-99% narrowing.  
Patients with either moderate or severe vasospasm were considered positive for cerebral 
vasospasm.  Ten percent of angiograms will be independently scored by a second neurosurgeon 
or neuroradiologist to assess inter-rater reliability.  Mismatch between exams were discussed at a 
team conference and a consensus as to vasospasm status was reached.   
1.6.13 Long Term Outcomes 
The dependent variables in this study were long term outcome scores on the MRS and GOS.  
These scores were collected as part of the parent study at 3 months and 6 months after aneurysm 
rupture. The GOS, a clinical observation scale, categorizes functional outcomes into five levels 
ranging from 1 to 5 with 1 indicating death and 5 indicating good recovery  (Jennett & Jennett, 
1976) (See Appendix A).  Inter-rater reliability has been reported from 68 – 95% with kappa 
values from .62 to .79 (Gennarelli, Spielman, Langfitt, Gildenberg, Harrington, Jane, Marshall, 
Miller, Pitts et al., 1982) and correlates well with severity of illness.  The GOS has wide 
acceptance and established validity (Jennett, Bond, Jennett, & Bond, 1975; Maas, Braakman, 
Schouten, Minderhoud, van Zomeren et al., 1983).  Inter-rater reliability was within the 
acceptable range when there is adherence to assessment guidelines, administration of a structured 
interview, and training of examiners (Wilson, Pettigrew, Teasdale et al., 1998).  Of the subjects 
enrolled in the parent study 79% had GOS measured at 3 months, 74% have 6 month 
measurements.    
The Modified Rankin Scale is a measure of functional recovery and incorporates mental 
and physical adaptations to the neurological deficits following a neurological injury.  It is easy to 
use and has been widely adopted for use in stroke trials. The MRS score ranges from 0 (no 
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symptoms at all) to 6 (death) (See Appendix B).  Inter-observer kappa were .56 and weighted 
kappa were .91 (Sulter, Steen, De Keyser et al., 1999).  Of the subjects enrolled in the parent 
study 79% had MRS measured at 3 months, 74% have 6 month measurements.    
1.6.14 Severity of Injury 
Severity of injury was measured by the Hunt & Hess (Appendix C) and size of hemorrhage was 
measured by the Fisher Grade score (Appendix D). Both of these scores were collected from 
medical records as part of the parent study.  The Hunt and Hess grading system is based on 
clinical symptoms at the time of admission, with scores ranging from zero (0), indicating no 
clinical symptoms, to five (5), indicating a comatose state (Hunt, 1983).  The Hunt and Hess 
scale inter-rater reliability is acceptable with a kappa value of 0.41 (p=.0005) (Oshiro, Walter, 
Piantadosi, Witham, & Tamargo, 1997). Hunt and Hess scores have also been correlated with 
infarct related to CV (Gruber et al., 1998). 
The Fisher scoring system is a tool that measures the size of hemorrhage based on 
amount and distribution of blood on CT scan. Fisher scores range from zero (0) indicating no 
blood noted on CT scan, to four (4) indicating intracerebral or intraventricular clot with diffuse 
or no blood in the subarachnoid space (Fisher, 1980). Ogilvy and associates found Fisher grade 
to have excellent inter-rater reliability with kappa value of 0.9 (Ogilvy & Carter, 1998). Higher 
Fisher scores have been correlated with CV after SAH (Lasner & Raps, 1997; McGirt et al., 
2003). 
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1.6.15 Data Management 
Covariates, CV status, and severity of injury measures were collected and entered into the 
existing database using an automated data entry and verification system (Teleform).  Data was 
stored in password protected computers and locked offices of research associates of the parent 
study.  The new genotype data from this proposed project was stored in a database within a 
password protected computer with no other personal identifiers. 
1.6.16 Preliminary Data Analysis Plan 
Initially data was screened for missing data, outliers, and possible confounding factors and to 
assess whether underlying statistical assumptions for the planned analysis are satisfied.  All 
attempts were made to retrieve missing data from the parent study databases or medical records 
of the subjects.  Appropriate descriptive statistics (based on the level of measurement and the 
empirical data distribution) were computed for all variables and were summarized for the entire 
sample and based on CV, long term outcomes, tSNP’s genotypes and their combination.  
1.6.17 Justification of Sample Size for specific aims 
Specific Aim #1:  Describe the distribution of Lys198Asn and tSNP of the ET-1 gene in 
individuals recovering from aSAH.  There were 282 subjects with DNA collected for analysis.  
There was no effect size associated with this aim since it will describe the distribution of the 
genotypes.   
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Specific Aim #2:  Describe the relationship between the ET-1 polymorphisms and CV 
after aSAH.  An estimated sample size of 108 achieves 80% power to detect an effect size of 
0.300 with a significance level of α=.05.  At this time there are 144 subjects with angiographic 
CV status.  A sample of 144 will achieve a 91% power with an effect size of 0.30 with a 
significance level of α=.05. 
Specific Aim #3: Describe the relationship between the ET-1 polymorphisms and long 
term outcomes after aSAH. An estimated sample size of 167 achieves 80% power to detect an 
effect size of 0.500 with a significance level of α=.05.  At this time there are 213 subjects with 
long term outcomes measurement.  A sample of 213 will achieve an 87% power with an effect 
size of 0.30 with a significance level of α=.05. 
Specific Aim #4:  Describe the CSF ET-1 protein expression for the 3 days prior to CV 
measurement. An estimated sample size of 150 will achieve 80% power at significance level of 
α=.05.  There are approximately 40 patients with ET-1 protein levels measured for the 3 days 
prior to CV.  A sample of 40 will achieve a 20% power with a significance level of α=.05. 
Specific Aim #5:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, of individuals with and without CV over time for the first 14 days after aSAH.  An 
estimated sample size of 150 will achieve 80% power at significance level of α=.05.  There are 
approximately 40 patients with ET-1 protein levels and genotyping for the 3 days prior to CV.  A 
sample of 40 will achieve a 20% power with a significance level of α=.05. 
Specific Aim #6:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, of individuals with and without CV over time for the 3 days prior to CV 
measurement.  An estimated sample size of 150 will achieve 80% power at significance level of 
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α=.05.  There are approximately 40 patients with ET-1 protein levels and genotyping for the 3 
days prior to CV.  A sample of 40 will achieve a 20% power with a significance level of α=.05. 
Specific Aim #7: Describe the CSF ET-1 protein expression over the first 14 days after 
aSAH, in association with Lys198Asn and tSNP’s, and its potential relationship with long term 
outcomes.  An estimated sample size of 150 will achieve 80% power at significance level of 
α=.05.  There are approximately 100 patients with ET-1 protein levels and long term outcomes 
measures.  A sample of 100 will achieve a 33% power with a significance level of α=.05. 
1.6.18 Data analysis for specific aims 
Specific Aim #1:  Describe the distribution of Lys198Asn and tSNP of the ET-1 gene in 
individuals recovering from aSAH.  Frequency counts and marginal percentages were used to 
describe the frequency distribution for functional SNP and tSNP’s of individuals recovering from 
SAH. Point and interval estimates (95% confidence intervals) for the prevalence of the functional 
SNP and tSNP will also be obtained. 
Specific Aim #2:  Describe the relationship between the ET-1 polymorphisms and CV 
after aSAH.  Chi Square analysis will be used to investigate the relationship between ET-1 
polymorphisms and CV with a significance level of α=.05.  The null hypothesis is that the 
probability of having vasospasm is equal for each genotype (homozygous wild, homozygous 
variant, and heterozygous).  A 2x3 chi square will be used in this analysis.  There will be two 
levels of CV (CV positive and CV negative) and three levels of genotyping.  
Specific Aim #3: Describe the relationship between the ET-1 polymorphisms and long 
term outcomes after aSAH.  Chi Square analysis will be used to investigate the relationship 
between ET-1 polymorphisms and long term outcomes with a significance level of α=.05.  The 
 39 
null hypothesis for the long term outcome MRS is that the probability of having a MRS score is 
equal for each.  For the long term outcome MRS a 3x7 chi square analysis will be used.  There 
will be three levels of genotyping and 7 levels of MRS measurement. The null hypothesis for the 
long term outcome GOS is that the probabilities of having a GOS score is equal for each 
genotype.  For the long term outcome GOS a 3x5 chi square analysis will be used.  There will be 
three levels of genotyping and 5 levels of MRS measurement. 
Specific Aim #4:  Describe the CSF ET-1 protein expression for the 3 days prior to CV 
measurement.  Logistic regression will be used to compare daily ET-1 CSF levels in patients 
with and without CV while controlling for the influence of covariates (i.e. race, age, Fisher 
grade).  This analysis will examine ET-1 CSF levels over time.  Logistic regression will be able 
to estimate the probability of the presence or absence of CV based on CSF ET-1 protein levels 
while controlling for the covariates.   
Specific Aim #5:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, of individuals with and without CV over time for the first 14 days after aSAH. 
Trajectory analysis will be used to dichotomize subjects into high or low ET-1 levels and then 
logistic regression will be used to compare the ET-1 CSF levels of subjects with and without CV 
while controlling for the ET-1 genotypes and covariates (i.e. age, race, Hunt & Hess, and Fisher).  
Trajectory analysis will plot the trajectory of ET-1 CSF levels for the first 14 days.  These 
trajectories will be plotted based on CV status (CV negative and CV positive.  The trajectories 
are then evaluated for differences at the significance level of α=.05.   
Specific Aim #6:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, of individuals with and without CV over time for the 3 days prior to CV 
measurement.  Logistic regression will be used to compare daily ET-1 CSF levels in patients 
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with and without CV while controlling for the ET-1 genotypes and the influence of covariates 
(i.e. race, age, Fisher grade).  This analysis will examine ET-1 CSF levels over time.  Logistic 
regression will be able to estimate the probability of the presence or absence of CV based on 
CSF ET-1 protein levels while taking into account the genotype and controlling for the 
covariates.   
Specific Aim #7: Describe the CSF ET-1 protein expression over the first 14 days after 
aSAH, in association with Lys198Asn and tSNP’s, and its potential relationship with long term 
outcomes.  Trajectory analysis will be used to dichotomize subjects into high or low ET-1 levels 
and then logistic regression will be used to compare the ET-1 CSF levels of subjects related to 
their long term outcomes while controlling for the ET-1 genotypes and covariates (i.e. age, race, 
Hunt & Hess, and Fisher).  Trajectory analysis will plot the trajectory of ET-1 CSF levels for the 
first 14 days.  These trajectories will be plotted based on their long term outcome status. The 
trajectory groups will have 5 groups for the GOS analysis and 7 groups for the MRS analysis.  
The trajectories are then evaluated for differences at the significance level of α=.05.   
1.7 LIMITATIONS 
This study has limitations worth mentioning.  All data was collected as part of parent studies.  
Therefore, any additional demographic data cannot be collected if it was not collected as part of 
the parent studies.  Additionally, statistical methods were chosen based on their ability to inform 
of possible associations in this study.  The findings of this study are limited to the aSAH 
population and cannot be generalized to all causes of SAH.   
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1.8 PUBLICATIONS 
The following is a published abstract directly relevant to this research proposal, although 
cerebral vasospasm is a major contributor to ischemia and poor outcomes following aneurysmal 
subarachnoid hemorrhage (aSAH); little is known regarding its etiology.  It has been suggested 
that endothelin-1 (ET-1), a potent vasoconstrictor, is related to the formation of CV.  However, 
ET-1’s temporal role in CV has not been well established, decreasing clinicians’ ability to use it 
as a potential biomarker of CV.  We hypothesis that cerebrospinal fluid (CSF) ET-1 levels after 
aSAH would be higher in pts with CV.  Subjects (N=40), were prospectively recruited for an on-
going NIH funded study [90% White (n=36); 72.5% female (n=29)].  The inclusion criteria were 
patients age 18-75, with a diagnosis of aneurysmal SAH (Fisher grade ≥2), access to CSF, and a 
cerebral angiogram.  Persons with a history of a neurologic disease were excluded.  
Presence/absence of CV was determined by cerebral angiogram independently read by a 
neuroradiologist. CSF samples were drawn twice a day for 72 hours before angiogram.  CSF ET-
1 levels were quantified using ELISA and Area Under the Curve (AUC) was calculated for 24, 
48, and 72 hours before angiogram.  Graphic analysis, descriptive statistics, t-tests, and ANOVA 
were used to analyze relationships.  Of the 40 subjects, 16 developed CV within 14 days. Mean 
72 hour AUC for the entire sample was 42.07.  Mean 72 hour AUC was higher in the CV present 
group (M=50.9 vs. 36.2; F=3.172 P=.036).  There was no significant difference in AUC at 24 
and 48 hours prior to CV.  The observed elevation in ET-1 CSF concentrations provides clinical 
evidence that ET-1 may be involved in the pathogenesis of CV in patients after SAH (Gallek et 
al., 2006). 
 The following abstract was submitted to the Society of Critical Care Medicine and is 
directly relevant to this research proposal.  Cerebral Vasospasm (CV) is a major contributor to 
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ischemia and poor outcomes following aneurysmal subarachnoid hemorrhage (aSAH), little is 
known regarding its etiology.  It has been suggested that endothelin-1 (ET-1), a potent 
vasoconstrictor, is related to the formation of CV.  Genetic variations of ET-1 may influence the 
occurrence of CV or long term outcomes.  The purpose of this study was to investigate ET-1 
tagging SNP’s (tSNP’s) relationship to CV and to long term outcomes.  Subjects (N=229), were 
prospectively recruited for an on-going NIH funded study [100% Caucasian; 72% female 
(n=165)].  The inclusion criteria were patients age 18-75, with a diagnosis of aneurysmal SAH 
(Fisher grade ≥2), and access to DNA.  Persons with a history of a neurologic disease were 
excluded.  Presence/absence of CV was determined by cerebral angiogram independently read 
by a neurosurgeon.  Genotyping of 7 tSNP’s and 1 functional SNP was performed using an ABI 
Prism® 7000 Sequence Detection System and TaqMan® assays.  This is a highly automated, 
high throughput genotyping method for SNP’s.  Modified Rankin Score (MRS) was collected at 
6 months post aneurysm rupture.  These scores were collected by a trained neuropsychological 
technician.  Graphic analysis, descriptive statistics, and chi-square were used to analyze 
relationships.  Of the 229 subjects, 144 had cerebral angiograms, and 67 developed CV within 14 
days. Of the 8 SNP’s that were investigated, RS2070699 showed a significant relationship with 
CV (p=0.010).  RS1476046, RS2071943 and RS2070699 both showed a significant relationship 
with MRS measured at 6 months (p=0.38, p=0.045 and p=0.006 respectively).  No other SNP’s 
showed significant relationships with CV or MRS.  By investigating all of the tagging SNP’s 
involved with ET-1 all of the genetic variation within the ET-1 gene is accounted for in this 
analysis.  The variant allele of RS2070699 is associated with CV and with a worse MRS at 6 
months after injury.  The variant allele of RS1476046 and RS2071943 are associated with a 
better MRS at 6 months after injury   The significant relationship found between a tSNP and CV 
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or long term outcomes is the first step that may allow clinicians to screen for SNP’s that are 
associated with the development of CV. This screening will allow clinicians to focus resources 
on patients with increased risk of CV and worse outcomes. 
1.9 HUMAN SUBJECTS 
1.9.1  Human Subjects Involvement and Characteristics 
All subjects were recruited as part of a parent study that investigates biomarkers of acute and 
long term recovery of aSAH patients.  There were approximately 280 subjects with DNA 
available for genotyping.  Of those 250 subjects approximately 150 subjects have angiographic 
CV data available for analysis.  There was also a subset of approximately 210 subjects with long 
term outcome data available for analysis.  Inclusion criteria for this study were:  1) Male or 
female, 2) 18-75 years of age, 3) A DNA sample must be available for genotyping.  Exclusion 
criteria are:  1) SAH due to trauma, mycotic aneurysm, arterial-venous malformation, or from an 
unknown source and 2) pre-existing neurological disease or injury.  No exclusion criteria were 
based on race, gender or ethnicity.  Children below the age of 18 account for a low incidence of 
aSAH (<.001) and were excluded from this study.  No special classes of subjects (e.g., fetuses, 
neonates, pregnant women, children, prisoners, institutionalized individuals or others) who may 
be considered vulnerable populations were recruited into the parent study or this study. 
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1.9.2 Sources of Data  
Demographic data was collected as part of the parent studies.  The parent studies collected 
baseline data, age, gender, race, past medical history, Fisher Grade and Hunt & Hess Score from 
the medical records.  No additional demographic data were collected as a part of this study. 
All biological and DNA specimens were collected as part of the parent studies and are 
labeled with the unique study identification number, and date and time drawn.  Subjects had 10cc 
of whole blood drawn on day one of enrollment into the parent studies.  The tube of blood was 
delivered to Dr. Conley’s laboratory with no personal identifiers.  The sample was logged in and 
centrifuged, the white cells removed, and DNA extracted from the white cells using a simple 
salting out procedure(Miller et al.).  All DNA is stored in 1X TE buffer at 4°C.  Cerebrospinal 
fluid (CSF) specimens were obtained twice daily from either extraventricular drains (EVD) or 
via lumbar drains (LDs). All samples were then immediately frozen in cryogenic vials to –20oC. 
At the end of 14 days when all collections were completed the specimens were stored in –80oC 
freezers until analysis.  The ET-1 CSF level analysis took place in Dr. Poloyac’s tissue and 
animal laboratory located in the School of Pharmacy.  No additional specimens were collected as 
part of this study.   
Outcome data was also collected as part of the parent studies at the 3 months and after 
aneurysm rupture.  No additional outcome data were collected as part of this study.  All data is 
stored with the subject’s unique identification number. 
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1.9.3 Recruitment and Retention  
There were no special recruitment or retention plans for this study. Since this was a study that 
analyses samples and data that were previously collected the investigator had no contact with 
potential or current subjects.   
1.9.4  Potential Risks to the Participants  
There were no physical risks to the research subjects due to this study's analysis of existing 
samples.  However, there are potential anticipated risks to confidentiality.  All samples and 
previously collected data were labeled with the parent study’s identification number.  The master 
list that links the subjects name with the study identification number is kept by the parent study’s 
principal investigator.  All data from the parent study was stored in a locked file cabinet or on a 
password protected computer.  A new computerized database was started for the collection of the 
genotype data.  This database was maintained by the principal investigator and the faculty 
mentor to ensure correct data entry and minimal risk to subject confidentiality.   
1.9.5 Procedures to Minimize Risks  
To protect the subjects from the risk to confidentiality the following procedures were used.  All 
samples and subjects were identified by unique identification numbers.  The master list of the 
subject’s identification was maintained by the principal investigators of the parent study.  All 
data collected were maintained on password protected computers.   
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1.9.6  Importance of Knowledge to be Gained  
The risks to subjects were limited to breach of confidentiality. The importance of the knowledge 
to be gained is significant.  This study will advance nursing research in human genetics.   The 
results of this study may also affect nursing interventions in the care of patients after aSAH by 
helping nurses to identify and focus resources on patients at higher risk of CV and poor long-
term outcomes.  The results of this study will also promote the integration of nursing process into 
the delivery of genomics-based healthcare services. Finally, the results of this study will add to 
the literature and encourage development of interventions aimed at decreasing CV after SAH and 
improving long term outcomes with minimal risk to the subjects.       
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2.0  SUMMARY OF STUDY  
The study followed the terms of the proposal except for the statistical analysis used to analyze 
the specific aims.  Each specific aim will be restated and the statistical analysis that was used 
will be described in detail.  Of the 7specific aims, 5 are included in the two manuscripts within 
this document.  The two specific aims that were not included in the manuscripts will also be 
addressed below.   
Specific Aim #1:  Describe the distribution of Lys198Asn and tSNP of the ET-1 gene in 
individuals recovering from aSAH.  This specific aim was addressed in the manuscript entitled 
‘Endtothelin-1 Tagging SNPs and Their Relationship to Outcomes Following Aneurysmal 
Subarachnoid Hemorrhage’. 
Specific Aim #2:  Describe the relationship between the ET-1 polymorphisms and CV 
after aSAH.  The chi-square analysis was not used as stated in the proposal.   Binary logistic 
regression was used as a predictive model of CV.  The individuals SNP’s genotypes were used as 
the predictor.  Fisher grade and age were controlled for in this model.  This specific aim was 
addressed in the manuscript entitled ‘Endothelin-1 Tagging SNPs and Their Relationship to 
Outcomes Following Aneurysmal Subarachnoid Hemorrhage’. 
Specific Aim #3: Describe the relationship between the ET-1 polymorphisms and long 
term outcomes after aSAH.  Multinomial logistic regression replaced the chi-square analysis that 
was originally proposed.  The genotypes were used as the predictor, and the model controlled for 
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age and Hunt& Hess grade.  This specific aim was addressed in the manuscript entitled 
‘Endothelin-1 Tagging SNPs and Their Relationship to Outcomes Following Aneurysmal 
Subarachnoid Hemorrhage’. 
Specific Aim #4:  Describe the CSF ET-1 protein expression for the 3 days prior to CV 
measurement.  This specific aim is addressed in the manuscript entitled ‘Endothelin-1 
Cerebrospinal Fluid Levels are Associated with the Development of Cerebral Vasospasm in 
Aneurysmal Subarachnoid Hemorrhage Patients’. 
Specific Aim #5:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, of individuals with and without CV over time for the first 14 days after aSAH.  
Trajectory analysis was used to dichotomize the subjects into high or low ET-1 CSF level groups 
based on their ET-1 CSF levels for the first 14 days after aneurysm rupture.  Binary logistic 
regression was used to determine the relationship between the ET-1 level, ET-1 genotypes, and 
CV.  CV was the outcome variable in this model.  Age and Fisher grade were controlled for in 
the model.  ET-1 level groups and genotypes were the predictors in this model.   
Results:  A total of 62 subjects were included in this analysis.  These subjects were all 
Caucasian, predominantly female (n=47, 75.8%), and had a mean age of 55.18 ±10.49 years old.  
Twenty-seven (43.5%) of the 62 subjects were CV positive.  ET-1 level groups and ET-1 
genotypes were not significant predictors of CV in this model.   
Conclusion: The lack of a significant finding is not surprising in this case.  The ET-1 
level groups were based on the ET-1 levels measured over a 14 day period.  In the attached 
manuscript it is reported that a difference in ET-1 CSF levels are seen in the 72 hours before CV 
occurs.  The other 11 days worth of ET-1 levels may not have any influence on CV occurrence.  
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Therefore, this analysis even with the genotype data included did not find any significant 
differences.   
Specific Aim #6:  Describe the CSF ET-1 protein expression, in relation to Lys198Asn 
and tSNP’s, for the 3 days prior to CV measurement.  This specific aim is addressed in the 
manuscript entitled ‘Endothelin-1 Tagging SNPs and Their Relationship to Outcomes Following 
Aneurysmal Subarachnoid Hemorrhage’. 
Specific Aim #7: Describe the CSF ET-1 protein expression over the first 14 days after 
aSAH, in association with Lys198Asn and tSNP’s, and its potential relationship with long term 
outcomes.  Trajectory analysis was used to dichotomize the subjects into high or low ET-1 CSF 
level groups based on their ET-1 CSF levels for the first 14 days after aneurysm rupture.  Binary 
logistic regression was used to determine the relationship between the ET-1 level, ET-1 
genotypes, and long term outcomes.  MRS or GOS at 3 or 6 months were the outcome variables 
in this model.  Age and Hunt & Hess grade were controlled for in the model.  ET-1 level groups 
and genotypes were the predictors in this model.   
Results: There were 74 subjects with outcomes measured at 3 months.  These subjects 
were Caucasian, the majority were female 52 (70.3%), and had a mean age of 55.55 ± 9.90 years 
old.  There were also 64 subjects that had outcomes measured at 6 months.  All were Caucasian, 
47 (73.4%) were female, and the mean age was 57.14±9.66 years old.  ET-1 level groups and 
genotypes were not significant predictors in this model.   
Conclusion:  The lack of significant findings may have two possible causes.  The first is 
that ET-1 levels and ET-1 genotypes do not have a major role in long-term outcomes.  The 
second explanation is that the long-term outcome measures used here are not specific enough to 
detect outcomes changes influenced by ET-1 CSF levels or ET-1 genotypes.  The GOS and MRS 
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are measure of global functional outcomes.  It may be more appropriate to investigate specific 
neuropsychological outcomes to elucidate differences in long-term outcomes.   
This study supports the use of ET-1 for use as a protein biomarker and a genetic 
biomarker in the prediction of CV following aneurysmal SAH.  The ET-1 CSF levels 72 hours 
before angiography are significantly higher in the CV positive group when compared to the CV 
negative group.   The SNP rs2070699’s variant allele was also a predictor of the occurrence of 
CV.   This relationship was a dose dependent relationship.  An individual with no variant allele, 
homozygous wild type, had the lowest odds of having CV; a heterozygous individual had almost 
3 times the odds of having CV.  Finally, a homozygous variant individual (two copies of the 
variant allele) had 8 times the odds of having CV when compared to the homozygous wild-type 
individual.    
The investigation of long-term outcomes and ET-1 levels/ET-1 SNPs produced no 
significant findings.  While this is disappointing, it can be explained in one of two ways.  The 
first is that ET-1 levels and ET-1 genotypes do not have a major role in long-term outcomes.  
The second explanation is that the long-term outcome measures used here are not specific 
enough to detect outcome changes influenced by ET-1 CSF levels or ET-1 genotypes.   
The strengths of this study are numerous, 1) angiography was used as a definitive 
diagnosis of CV.  Therefore, the chance of misdiagnosis is all but eliminated.  2) It is the first 
study to date that controls the CSF drainage volume in relation to ET-1 concentration.  This may 
have made our study more sensitive to changes in ET-1 levels in the CSF.  3) This is the first 
study to date that investigates ET-1 SNPs in the SAH population. 
There are limitations to this study.  The subset of patients with ET-1 CSF levels may 
have been in a more critical state during their hospitalization.  Our samples of CSF were taken 
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from patient with CSF drainage catheters.  To receive a catheter the patient must be more 
critically ill than someone without.  The subset of patients with angiographies would also have 
been in a more critical state.  Repeat angiographies are typically performed for a change in 
neurologic exam.  Therefore, this would also skew the sample to include patients in a more 
critical state.  The patients included in the analysis of the ET-1 SNPs were limited to Caucasians.  
This is due to the fact that distribution of alleles and tagging SNPs themselves are different 
between races.  The small number of minorities presenting to the UPMC Presbyterian hospital 
with a diagnosis of SAH did not allow for proper analysis of genotypes in minorities.  Therefore, 
the results from this study will not apply to minorities.   
Future studies would include continuing the above study with larger sample numbers, 
especially the subset of ET-1 CSF subjects.   In addition larger minority numbers would be 
needed to investigate the genetic relationship of ET-1 and outcomes following SAH.  While 1 
ET-1 tagging SNP was associated with CV, the specific cause of this association was not 
elucidated.  Further studies are needed to investigate the area of the ET-1 gene that the tagging 
SNP represents.  This investigation would focus on finding functional SNPs that would change 
the protein structure of ET-1 thereby causing a change in ET-1 function.  Additional work 
exploring the relationship between ET-1 genotypes and/or phenotype and outcome while 
controlling for angiographic CV may also show that these are significant predictors of outcome 
in subgroups of individuals with or without CV.  Finally, other possible biomarkers of CV and 
long-term outcomes need to be investigated in a similar fashion as above.  By exploring 
biomarkers it is the aim to predict and prevent poor outcome following SAH.   
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3.0  MANUSCRIPT 1: ENDOTHELIN-1 CEREBROSPINAL FLUID LEVELS ARE 
ASSOCIATED WITH THE DEVELOPMENT OF CEREBRAL VASOSPASM IN 
ANEURYSMAL SUBARACHNOID HEMORRHAGE PATIENTS 
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3.1 LETTER TO EDITOR 
 
April 30, 2008 
 
Vladimir Hachinski, MD 
Editor 
Stroke Editorial Office,  
University of Western Ontario Research Park 
100 Collip Circle, Suite 116 
London, ON, Canada N6G 4X8 
 
Dear Dr. Hachinski: 
 
Please find enclosed the manuscript entitled “Endothelin-1 Cerebrospinal Fluid Levels 
are Associated with the Development of Cerebral Vasospasm in Aneurysmal Subarachnoid 
Hemorrhage Patients.” that we would like for you to consider for publication in Stroke.  The 
findings reported in this manuscript demonstrate in a large patient population that there is a 
significant temporal relationship between CSF endothelin-1 concentrations and the subsequent 
development of vasospasm as definitively determined by angiography.  These findings provide 
much needed clarity as to the role of endothelin-1 in relation to the development of cerebral 
vasospasm and also represent one of the largest studies in this patient population.  The authors 
have reviewed this manuscript and appreciate the time and effort committed by all for peer 
review.  The content of this manuscript has not been published before and is not being 
considered for publication elsewhere.  We look forward to future correspondence.  All 
communication can be addressed to the following: 
 
Samuel M. Poloyac 
Assistant Professor 
Department of Pharmaceutical Sciences 
University of Pittsburgh 
School of Pharmacy 
1014 Salk Hall  
Pittsburgh, PA 15261 
poloyac@pitt.edu 
412-624-4595 
 
 
Sincerely, 
 
 
Samuel M. Poloyac, Pharm.D., Ph.D. 
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3.2.1 Abstract  
Background and Purpose: Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease 
that affects approximately 25,000 people a year in the United States.  Cerebral vasospasm (CV) 
is a common complication after SAH that results from narrowing of the cerebral arteries.  The 
underlying mechanism of CV remains unclear.  Endothelin-1 (ET-1) is a vasoconstrictor that 
may play a role in the pathogenesis of CV.  At this time no clear temporal relationship has been 
established between ET-1 levels and CV.  The purpose of this study was to examine changes in 
volume controlled ET-1 levels in CSF in the time before angiographic measurement of CV, and 
to investigate the relationship between CSF ET-1 and CV in SAH patients.  Methods: Forty 
patients with SAH were recruited as part of this study.  Cerebrospinal fluid drainage volume was 
controlled for in these samples and expressed as elimination rate (pg/hr).  Cerebral vasospasm 
was determined by angiography as part of medical care.  ET-1 levels were measured using 
chemiluminescent ELISA kits.  Results:  The average ET-1 elimination rate for the 72 hours 
before angiography was 4.35±3.02 pg/hr for the CV negative group and 7.94±6.47pg/hr for the 
CV positive group.  The ET-1 elimination rate for the 72 hours before angiography was a 
significant predictor of CV in this model when controlling for age and Fisher grade (p=0.026).  
Conclusions:  This study showed a temporal relationship between ET-1 levels 72 hours before 
CV measurement and the development of CV after SAH.  This study supports the potential use 
of ET-1 as an index of CV development.   
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3.2.2 Introduction 
Subarachnoid hemorrhage (SAH) occurs in approximately 1 out of 10,000 people in the United 
States each year (Longstreth et al., 1985), accounting for 10% of the stroke population. It is 
associated with a mortality rate of 30-50% (Sobey & Faraci, 1998), most often originating as an 
aneurysmal rupture of vessels of the circle of Willis (Longstreth et al., 1985).   Of those that 
survive the initial hemorrhage, 40-50% will suffer severe long term neurological disabilities 
(Sobey & Faraci, 1998).  These disabilities may include cognitive dysfunction and memory loss 
with an estimated cost of over $10,000 per person per year for long-term care (Lee et al., 2007) 
alone.       
Despite advances in neurosurgical treatments, the morbidity and mortality rate of SAH 
has not significantly improved over the past 40 years (Solenski, Haley, Kassell, Kongable, 
Germanson, Truskowski, & Torner, 1995).  Surgical methods of aneurysm securement have 
improved survival after the initial injury, yet these techniques do not appear to diminish the 
serious adverse consequences of cerebral vasospasm (CV), leaving long term survival rates 
relatively unchanged (Solenski, Haley, Kassell, Kongable, Germanson, Truskowski, & Torner, 
1995).   Cerebral vasospasm is a narrowing of the cerebral arteries that can result in delayed 
cerebral ischemia, further neurological damage, and stroke.   Cerebral vasospasm has a peak 
incidence of 3 to 12 days after the initial SAH (Newell, Eskridge, Mayberg, Grady, & Winn, 
1989).  Angiographic CV occurs in up to 70% of patients with SAH (Dorsch, 2002) and 
symptomatic vasospasm (angiographic vasospasm with an associated change in neurological 
assessment) affects nearly one third of all patients.  Without appropriate treatment CV can result 
in death in 30% of patients and permanent disability in 34% of patients (Dorsch, 2002), thereby 
serving as a major complication affecting the morbidity and mortality of SAH. CV has been 
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correlated with a 1.5 to 3 fold increase in mortality in the first 2 weeks after SAH and occurs in 
30-70% of all patients with a SAH (Treggiari-Venzi, Suter, & Romand, 2001).    
While the underlying mechanism for CV remains unknown, individuals who have an 
increased amount of blood in the subarachnoid space have a greater risk of developing CV and 
the CV is likely to be more severe (Treggiari-Venzi, Suter, & Romand, 2001).  The cause of CV 
is likely to be multifactorial in nature, such that the balance between normal auto-regulatory 
controls results in the production of vasoconstrictive mediators.  Although the predominant 
mediators of CV remain obscure, several vasoactive metabolites have been shown to be present 
in the CSF of patients after SAH.  These mediators include endothelin-1 (Mima et al., 1989; 
Petzold, Einhaupl, Dirnagl, & Dreier, 2003; Seifert et al., 1995; H. Suzuki, Sato, Suzuki, Oka et 
al., 1990), 20 HETE (Cambj-Sapunar, Yu, Harder, & Roman, 2003; Poloyac, Reynolds, Yonas, 
& Kerr, 2005), vasopressin (Mather, Ang, & Jenkins, 1981; Nishihashi, Trandafir, Wang, Ji, & 
Kurahashi, 2005), proinflammatory cytokines (Kwon & Jeon, 2001), angiotensin, and adhesion 
molecules (Lin et al., 2005; Lin et al., 2007) which have been investigated in clinical or animal 
models.  One of these mediators with moderate support is endothelin-1 (ET-1).  ET-1 is a long 
lasting and potent vasoconstrictor (H. Suzuki, Sato, Suzuki, Takekoshi et al., 1990; Yamaji et al., 
1990).   It directly binds to receptors on vascular smooth muscle cells leading to calcium 
mobilization and smooth muscle contraction (Davie et al., 2002) thereby influencing vasomotor 
tone.  Vascular smooth muscle contraction is observed at ET-1 concentrations as low as 3 X 10 -
11 mol/L (Hirata et al., 1989).    
Several groups have investigated the role of ET-1 in CV.  Initial studies showed an increase 
in the ET-1 concentrations in the CSF of patients with SAH compared to controls without SAH 
(H. Suzuki, Sato, Suzuki, Takekoshi et al., 1990).  Subsequent clinical studies demonstrated a 
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correlation of increased ET-1 production with the presence of symptomatic vasospasm 
(Fassbender et al., 2000; Kastner et al., 2005; Kessler, Pacheco, Lozzi, de Araujo, & Onishi, 
2005; Mascia, Fedorko, Stewart, Mohamed, terBrugge, Ranieri, & Wallace, 2001; Seifert et al., 
1995; K. Suzuki et al., 2000).  However, a clear temporal relationship between increased ET-1 in 
the CSF and occurrence of CV has yet to be reported.  The use of ET-1 levels as a biomarker of 
CV has remained elusive due to several factors which include 1) different means of defining CV 
through the literature 2) investigation of ET-1 levels in relationship to aneurysm rupture rather 
than relationship to occurrence of CV, 3) lack of control for the volume of CSF drained during 
normal medical treatment, and 4) lack of sensitivity of the assays used. Therefore, the purpose of 
this study was to examine changes in volume controlled ET-1 levels in CSF in the time before 
angiographic measurement of CV, and to investigate relationship between CSF ET-1 and CV in 
SAH patients. 
3.2.3 Subjects and Methods 
Patients 
Following approval of the institutional review board, patients were recruited for an ongoing NIH 
funded study (R01-NR004339) and informed consent was obtained from the patient or proxy.  
Inclusion criteria for the parent study were: adult patients (ages 18-75 years) with the diagnosis 
of SAH from a ruptured cerebral aneurysm verified by Digital Subtraction Angiography (DSA) 
or CT angiography (CTA) with a Fisher Grade > 1. The first forty patients from the parent study 
with both cerebrospinal fluid drains (via an external ventricular device catheter (EVD) or lumbar 
drain (LD)) and cerebral angiograms during the first 14 days after admission were included in 
this analysis. Patients were excluded from this study and the parent study if they had a 
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preexisting neurological disorder or if their SAH resulted from a mycotic aneurysm, arterio-
venous malformation, trauma, or an unknown source. Patients were admitted to the 
Neurovascular intensive care unit (NV-ICU) at the University of Pittsburgh Medical Center 
(UPMC) from July 2003 to August 2006.  All patients received standard nursing and medical 
care in the NV-ICU including triple-H therapy (hypertension, hemodilution, and hypervolemia), 
nimodipine, and early surgical or endovascular intervention.   
Demographic information 
Age in years, race, sex, Fisher grade and Hunt and Hess grade were extrapolated from the 
medical record.  Fisher grade and Hunt and Hess grade were assigned by the admitting 
neurosurgeon. 
CSF specimens 
Cerebrospinal fluid (CSF) specimens were obtained twice daily from EVDs or LDs placed by 
trained neurosurgeons. EVDs were placed into a lateral ventricle.  To obtain samples from the 
lateral ventricle, specimens were collected using sterile technique, drawn directly from the 
drainage catheter at the site closest to the patient and then immediately frozen in cryogenic vials 
at –20oC. After 14 days, all collections were completed and the specimens were stored at  
-80oC until analysis.   The total CSF volume drained since the last sample collection was also 
recorded at the time of sample collection.   
Cerebral Vasospasm 
Cerebral vasospasm was diagnosed by measuring the diameter of cerebral vessels as documented 
on cerebral angiography.  Cerebral angiography was conducted as standard of care on admission, 
as postoperative follow-up care, and/or in the event of a neurological deterioration.  The 
angiographic studies were interpreted and graded by neuro-radiologists and neurosurgeons at 
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UPMC for evidence and degree of vasospasm. The degree of vasospasm was represented as the 
percentage of narrowing in the cerebral vessels as follows: CV negative was 0 to 25% narrowing 
and CV positive was 26-99% narrowing.   
Measurement of ET-1 
CSF samples were assayed for ET-1 using the QuantiGlo® Human Endothelin-1 ELISA kit from 
R&D Systems (Minneopolis, MN, USA).  This assay employs the quantitative sandwich enzyme 
immunoassay technique with chemiluminesent detection.  Chemiluminescent kits were required 
in this analysis because typical colorimetric kits lacked sufficient sensitivity to allow for 
quantitative CSF ET-1 concentration measurements.  The standard curve was modified from the 
R&D recommendations to include 0.195, 0.39, 0.78, 1.56, 3.13, 6.25, & 12.5 pg/ml standards.  
Precision and accuracy of the modified standard curve range was evaluated with intra-assay and 
inter-assay coefficients of variation.  The intra-assay coefficients of variation were 14.1%, 
14.0%, and 13.2% for the 0.195, 1.56, and 12.5 pg/ml standards respectively.  The inter-assay 
coefficients of variation were 9.57%, 12.67%, and 9.0% for the 0.195, 1.56, and 12.5 pg/ml 
standards respectively.  This range of standards was used to cover the range of concentrations 
observed in the CSF of SAH patients.  A microplate luminometer (Model # 1420-012 Victor-
Wallac, Finland) was used to measure the intensity of the light emitted.   
Statistical Analysis 
SPSS version 14.0 was used for all analyses.  Values are presented in the tables and text as mean 
± SD.  ET-1 protein elimination rate was calculated in a similar manner to Shore et al (2004), 
with the following formula: 
Elimination Rate (pg/hr) = Concentration of Sample (pg/ml) X CSF Drainage (ml) 
                            Time Period (hr) 
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 The average elimination rate was calculated for 24 hours, 48 hours, and 72 hours before 
angiography.  The subjects were divided into vasospasm positive and vasospasm negative groups 
as previously defined.    Differences between vasospasm positive and vasospasm negative groups 
were investigated using chi-square analysis for categorical variables, and independent t-test for 
continuous variables.  Binary logistic regression was used to evaluate the association between 
average ET-1 elimination rate at 72 hours before, 48 hours before, and 24 hours before 
angiography and 72 hours after angiography, with the outcome measure of CV controlling for 
age and Fisher grade.  A significant difference was defined as p ≤ 0.05.   
3.2.4 Results  
Forty subjects with CSF ET-1measurements, demographic information, and angiographic data 
were analyzed.  These subjects were predominantly female (n=28; 70.0%) and Caucasian (n=36; 
90.0%).  The average subject age was 54.8 ± 10.3 years old.  In this sample 16 (40%) patients 
developed CV.  Demographic information in relationship to vasospasm is presented in Table 1.  
There were no significant differences in demographic characteristics between the two groups.  
There was an average of 5.35 CSF samples collected per subject.  Graphs of representative ET-1 
elimination rates versus time profile for 4 subjects are presented in Figure 2. 
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Table 1: Demographics (n=40) 
     CV Negative  CV Positive  p value 
Sex   Male   8 (20.0%)  4 (10.0%)  0.729 
  Female 16 (40.0%)  12 (30.0%) 
Age  Median  55.0   53.0    
  Mean (SD)  56.3 (9.2)  52.6 (11.7)  0.272 
Race  African-American 2 (5.0%)  2 (5.0%)  0.715 
  Caucasian  22 (55.0%)  14 (35.0%)   
Hunt &Hess  1   0 (0%)   0 (0%)   0.437   
Grade   
2   5 (12.5%)  2 (5.0%) 
   
  3   8 (20.0%)  9 (22.5%) 
  4   9 (22.5%)  3 (7.5%) 
  5   2 (5.0%)  2 (5.0%) 
Fisher  1   0 (0%)   0 (0%)   0.382 
Grade   
2   8 (20.0%)  2 (5.0%) 
 
  3   11 (27.5%)  9 (22.5%) 
  4   5 (12.5%)  5 (12.5%) 
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Figure 2: ET-1 elimination rate profiles of four subjects.  The vertical line represents 
angiographic measurement of cerebral vasospasm.  Subjects 1 and 2 were cerebral vasospasm 
negative.  Subjects 3 and 4 were cerebral vasospasm positive.   
  
The average ET-1 concentrations for the 24 hours before angiography for the CV 
negative and positive groups were 0.53±0.23 pg/ml and 0.58±0.47 pg/ml respectively.  The 48 
hours before angiography had ET-1 concentration levels of 0.54±0.29 pg/ml for the CV negative 
group and 0.59±0.63 pg/ml for the CV positive group.  The average ET-1 concentration for the 
72 hours before angiography was 0.60±0.39 pg/ml for the CV negative group and 0.67±0.63 
pg/ml for the CV positive group.  
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The average ET-1 elimination rates for the 24 hours before angiography for the CV 
negative and positive groups (3.91±2.71 pg/hr versus 6.01±4.84 pg/hr) or for the 48 hours before 
angiography for the CV negative and positive groups (3.79±2.49 pg/hr versus 6.73±5.91 pg/hr) 
were not significant predictors of CV, but the data showed trends towards significance (p=.054) 
at 48 hours before angiography (Table 2).  The average ET-1 elimination rate for the 72 hours 
before angiography was 4.35±3.02 pg/hr for the CV negative group and 7.94±6.47pg/hr for the 
CV positive group (Figure 3).  The 72 hour ET-1 elimination rate was a significant predictor of 
CV in this model when controlling for age and Fisher grade.    The average ET-1 elimination rate 
72 hours after angiography showed no significant difference between the CV negative group 
(3.65±2.26 pg/hr) and the CV positive group (4.91±3.69 pg/hr).   
 
Table 2: Results from Binary Logistic Regression for CV Positive Verses CV Negative Groups 
Average Elimination Rate Odds Ratio (with 95% CI)  SE   p 
72 Hours before Angiography 1.244 (1.027 to 1.508) 0.098   0.026* 
48 Hours before Angiography 1.225 (0.996 to 1.506) 0.105   0.054 
24 Hours before Angiography 1.190 (0.959 to 1.476) 0.110   0.114 
72 Hours after Angiography  1.183 (0.912 to 1.534) 0.133   0.205 
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Figure 3:  Average ET-1 elimination rate (pg/hr) 72 hours before angiographic measurement of 
vasospasm.  The horizontal bar indicates the mean of each group. 
3.2.5 Discussion 
The results from this study demonstrate that the average ET-1 elimination rate for the 72 hours 
before measurement of CV by angiography is a significant predictor of CV, while controlling for 
age and Fisher Grade (p=0.026).  The odds ratio of 1.244 indicates that for every increase of 1 
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pg/hr in the average elimination rate 72 hours before angiography the odds of having vasospasm 
is 1.2 times greater while controlling for age and Fisher grade.  A strong trend toward 
significance was found for the average ET-1 elimination rate for the 48 hours before angiography 
(p=0.054), whereas there was no significant difference in ET-1 elimination rate observed 72 
hours after angiography.  In addition, the concentration of ET-1 in the CSF of SAH patients with 
CV was 2.69 X 10-13 mol/L.  Although this concentration is below the concentration of 3 X 10 -
11 mol/L which has been shown to constrict vascular beds (Hirata et al., 1989), it is expected that 
the concentrations at the site of the vascular beds would be greater than the diluted concentration 
observed in the CSF sampling site.  Based on this data, we conclude that there is a temporal 
relationship between ET-1 elimination rate and the formation of CV, with elevated ET-1 
elimination rates observed in the CSF 72 hours prior to angiography.   
Our observation that ET-1 is elevated in the CSF of SAH patients is consistent with prior 
studies.  Specifically, our observations concur with Kessler and associates findings of an increase 
in ET-1 levels in the CSF of patients with CV (Kessler, Pacheco, Lozzi, de Araujo, & Onishi, 
2005).  In contrast Mascia et al. concluded that there was no temporal relationship of ET-1 levels 
in the CSF to CV, and that ET-1 levels were indicative of neuronal damage (Mascia, Fedorko, 
Stewart, Mohamed, terBrugge, Ranieri, & Wallace, 2001).  This difference in our findings may 
be attributed to numerous reasons.  First, our study was the first study that controls for the CSF 
drainage volume by investigating ET-1 elimination rate.  All of our subjects had continuous 
passive CSF drainage.  By investigating ET-1 elimination, we were able to control for subjects 
that drained variable amounts of CSF.  Therefore, the previously mentioned studies may have 
been insensitive to differences caused by not controlling for the volume of CSF.  
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Second, we used angiography as a definitive diagnosis of CV as compared to others who 
used transcranial Doppler ultrasonography.  While transcranial Doppler ultrasonography is an 
important tool in the diagnosis of vasospasm, there are instances where transcranial Doppler 
ultrasonography values may yield false negative or false positive results.  A diagnosis of CV by 
transcranial Doppler ultrasonography must also be accompanied by a change in the patient’s 
neurological exam.  However, there are cases where a subject may have an increase in 
transcranial Doppler ultrasonography velocities and not have a change in their neurological exam 
or an increase in velocity and neurological change from reasons other than CV (such as fever).   
In these cases, the subjects may be assigned incorrectly into a CV negative group when in fact 
there was some sort of compensation for the CV even though they were not showing any signs of 
neurological deterioration. Subjects may incorrectly be assigned into CV positive groups when 
there change in neurological assessment may have another underlying cause such as fever.  By 
using angiography to measure CV we have all but eliminated the chance of misdiagnosis.   
Third, we performed our analysis relative to the time of CV measurement by 
angiography.  Previous studies have based their analysis on the time from aneurysmal rupture.  
Because of the long period of time in which CV may occur (day 3 to day 14 post rupture) we 
changed the perspective of our study.  By changing the approach to analysis to consider time 
from CSF sampling and angiography for CV verification, we believe that we have better 
elucidated the temporal relationship of ET-1 levels in the CSF relative to the development of CV, 
thereby characterizing a novel temporal relationship between ET-1 and CV.   
Fourth, we utilized a chemiluminescent ELISA method for detection of ET-1 
concentrations in the CSF.  This detection method was necessary because colorimetric kits 
lacked adequate sensitivity to detect ET-1 concentrations in the CSF of our patient population.  
 70 
Furthermore, we modified the calibration curves to allow for appropriate validation of these 
assays for the measurement of CSF ET-1 concentrations with the majority of sample 
concentrations quantitated from the middle of the calibration curve.  Validation of this method 
allowed for analytical quantitation of ET-1 concentrations in the CSF.  Prior studies employing 
colorimetric assay methods would be expected to have adequate sensitivity to measure peak ET-
1 CSF concentrations, but would likely lack the sensitivity to quantitate low levels of ET-1 in 
non-spasm patients. 
Finally, this study collected more CSF samples at numerous time points than previous 
studies.  We were able to collect CSF every twelve hours and had an average of 5.35 samples per 
subject.  This collection process may have made this study more sensitive to changes in the ET-1 
levels of CSF.   
However, there are limitations to this study.  The first is the subset of SAH patients.  This 
study examined patients that had access to CSF samples (EVD or LD).  Patients with a drainage 
system for CSF are traditionally in a more critical state than patients without a drain, as was the 
case with this study’s subjects, demonstrated by Hunt and Hess Scores (Table 1).  However, it 
was not ethically sound to access patients without drains by performing lumbar punctures every 
twelve hours or to place drains in patients that did not have a clinical need for these invasive 
catheters.  Additionally, of the subjects presenting to the UPMC Presbyterian Health System for 
care after aneurysmal SAH, on average, 75% have a CSF drainage device placed during their 
care.  Due to the small number of patients who do not receive such a device, we have captured 
the majority of patients at risk for CV with our current study criteria.  We were able to only 
include patients that also had a cerebral angiography as a measure of the presence or absence of 
CV.  The majority of this study’s patients had a clinical need for an angiography (i.e. change in 
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level of consciousness).  By including patients that have a need for angiography the sample is 
skewed towards subjects that are in a more critical state.  Keeping in mind that up to 70% of 
patients with SAH have angiographic CV, but only 33% of patients have symptomatic 
CV(Dorsch, 2002) (angiographic CV with a neurological change), there is a large percentage of 
patients that may have CV that would not have an angiography for this study.    
The third limitation of this study was the relatively small number of patients in our 
sample.  Our sample size is limited by two major factors.  One, our patients need to have an EVD 
or LD to collect the ET-1 levels.  Not all patients clinically have a need for an EVD or LD, 
therefore that portion of the population was not included in this study.  In addition our sample 
size is limited by follow up angiography.  As stated above, the majority of angiograms are 
performed on patients that have a clinical neurological deterioration.  Future work should include 
a larger sample size to give more power to such a study.  We were however able to identify 
significant differences in ET-1 elimination 72 hours before angiographic cerebral vasospasm 
suggesting that the effect size was large enough to accommodate the small sample size.   
In summary, we found the average ET-1 elimination rate for the 72 hour period before 
angiogram to be predictive of CV when controlling for age and Fisher grade.  This suggests that 
an average increased exposure time to ET-1 increases the likelihood of CV development, 
suggesting a possible mechanism of CV, and that CSF ET-1 level may be used to predict patients 
at risk for CV. 
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4.0  MANUSCRIPT 2: ENDTOTHELIN-1 TAGGING SNPS AND THEIR 
RELATIONSHIP TO OUTCOMES FOLLOWING ANEURYSMAL SUBARACHNOID 
HEMORRHAGE 
4.1 INTRODUCTION 
There are approximately 25,000 cases of subarachnoid hemorrhage (SAH) in the United States 
each year (Longstreth et al., 1985) most of which occur in women at an average age of 55 years 
old (Sobey & Faraci, 1998).  Ninety five percent of cases of spontaneous SAH result from 
ruptured cerebral aneurysms (aSAH) (Sobey & Faraci, 1998).  The morbidity and mortality rate 
of aSAH has decreased little over the past 40 years (Solenski, Haley, Kassell, Kongable, 
Germanson, Truskowski, Torner et al., 1995) despite new surgical methods that have been 
developed to improve survival rates of the initial injury.  While surgery decreased the risk of 
aneurysmal rebleed, the frequency of secondary injuries became evident and survival from aSAH 
did not improve.  In great part due to the frequency of cerebral vasospasm (CV) (Solenski, 
Haley, Kassell, Kongable, Germanson, Truskowski, Torner et al., 1995).   
Cerebral vasospasm a decrease in diameter of the lumen of cerebral blood vessels, can lead to 
delayed cerebral ischemia, furthering neurological damage, and possibly ischemic stroke.  Worse 
outcomes have been associated with the presence of CV (Goto & Yamagata, 2006; Ratsep & 
Asser, 2001).  Cerebral vasospasm has been correlated with a 1.5 to 3 fold increase in mortality 
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in the first 2 weeks after aSAH (Treggiari-Venzi, Suter, Romand et al., 2001).  Cerebral 
vasospasm occurs with a peak incidence 3 to 12 days after the initial aSAH (Newell, Eskridge, 
Mayberg, Grady, Winn et al., 1989).  Cerebral vasospasm characterized by angiography is 
defined as angiographic CV, and may occur in up to 70% of patients with aSAH (Dorsch, 2002).   
There are few accurate predictors of CV including amount and distribution of blood on CT 
scan (categorized by Fisher grade), age, hypertension, cigarette smoking, and cocaine use 
(Conway & Tamargo, 2001; Qureshi et al., 2001).  However, these risk factors do not accurately 
predict the occurrence of CV.  While numerous causal factors of CV have been investigated 
(Cohen et al., 1995; Hatake et al., 1992; Kasuya et al., 1995; P. Kim et al., 1992; Onoue et al., 
1995; Sobey et al., 1996; Yamamoto et al., 1997), the search for a single factor has been 
disappointing; a complex multifactorial etiology is most probable (Hamann & Schimrigk, 1995).  
In addition, long term recovery from aSAH is a complex process with few known prognostic 
factors including severity of hemorrhage, clinical exam upon admission, age, and presence or 
absence of cerebral vasospasm. Of those that survive the initial hemorrhage, 40-50% will suffer 
severe long term neurological disabilities (Sobey & Faraci, 1998).  These disabilities may 
include cognitive dysfunction or physical dysfunction with an estimated cost of over $10,000 per 
person per year for long-term care alone (Lee et al., 2007). 
Genetic susceptibility may play a role in better identifying patients at a high risk of poor 
outcomes.  Once these risks are identified, closer monitoring and more aggressive interventions 
may be considered.  Genes predicting poor outcome also provide information about pathways 
involved in outcomes and may give rise to potential interventions to prevent and/or treat these 
poor outcomes.   
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Researchers have suggested that endothelin-1 (ET-1), a potent vasoconstrictor produced by 
the endothelial cells of the vasculature (H. Suzuki, Sato, Suzuki, Oka et al., 1990; Yanagisawa, 
Kurihara, Kimura, Tomobe, Kobayashi, Mitsui, Yazaki, Goto, & Masaki, 1988), may play a role 
in the etiology of CV (Mascia, Fedorko, Stewart, Mohamed, terBrugge, Ranieri, Wallace et al., 
2001; Seifert et al., 1995; Yamaji et al., 1990; Yanagisawa, Kurihara, Kimura, Tomobe, 
Kobayashi, Mitsui, Yazaki, Goto, Masaki et al., 1988).    Suzuki and associates reported 
increased levels of ET-1 in cerebrospinal fluid (CSF) of aSAH patients (H. Suzuki, Sato, Suzuki, 
Takekoshi et al., 1990).  Recent studies showed that increased CSF ET-1 levels are associated 
with the development of CV after aSAH (Kessler, Pacheco, Lozzi, de Araujo, Onishi et al., 
2005), thus supporting the role of ET-1 in the pathogenesis of CV.  A temporal relationship has 
also been described with increased CSF ET-1 levels occurring 72 hours before CV (Gallek et al., 
2008). 
ET-1 polymorphisms have been investigated in numerous vascular conditions.  
Conditions that have been investigated include essential hypertension (Stevens & Brown, 1995), 
preeclamptic pregnancy (Barden et al., 2001), cerebral small vessel disease (Gormley et al., 
2005), and arterial stiffness (Iemitsu et al., 2006), to name a few.  A functional polymorphism 
(Lys198Asn) of the gene encoding ET-1 has shown differences in vasculature reactivity (Iglarz 
et al., 2002).  The difference in vasculature reactivity caused by this polymorphism may have an 
effect on the presence of or severity of CV thereby influencing long-term outcomes.  Along with 
this known functional polymorphism, other polymorphisms in the gene for ET-1 may influence 
CV and long-term outcomes.   
The majority of genetic variation among people can be characterized by single nucleotide 
polymorphisms (SNPs).  These polymorphisms result in a single nucleotide being changed at a 
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frequency high enough to be recognized in the population.  It has been estimated that there are 
about 7 million common SNPs in the human genome (Botstein & Risch, 2003; Kruglyak & 
Nickerson, 2001).  There may be hundreds of SNPs associated with an individual gene such as 
the ET-1 gene.  Genotyping each of these numerous SNPs is time consuming and not cost 
effective.  Tagging SNPs allow researchers to genotype a single nucleotide polymorphism that 
represents a larger region of the gene. Therefore it is possible to account for genetic variation 
within a gene without genotyping every SNP in that chromosomal region.  By exploring all of 
the tagging SNPs of ET-1 all genetic variance can be accounted for in the ET-1 gene, including 
potentially functional polymorphisms.  To date there are no studies published that investigate 
ET-1 tagging SNPs or ET-1 functional SNPs and their association with CV, or outcomes 
following aSAH.  Additionally no studies have explored protein expression (ET-1 levels) in the 
Cerebrospinal Fluid (CSF) of individuals with and without CV after aSAH in light of genetic 
polymorphisms.   
The purpose of this study is to describe the distribution of the Lys198Asn polymorphism 
and tagging SNPs of the ET-1 gene in individuals recovering from aSAH.  This study will also 
investigate the relationship between the ET-1 genotypes and outcomes, including CV, global 
functional outcomes measured at 3 months, and global functional outcomes measured at 6 
months after aSAH. Finally this study will investigate, in a subset of the sample, the relationship 
of ET-1 CSF levels and ET-1 polymorphisms on CV following aSAH.   
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4.2 SUBJECTS AND METHODS 
Patients 
Following approval of the institutional review board and after obtaining informed consent from 
the patient or next of kin 250 patients were recruited as part of an ongoing NIH funded study 
(RO1NR004339).  Inclusion criteria were: adult patients (ages 18-75 years) with the diagnosis of 
aSAH verified by Digital Subtraction Angiography (DSA) or CT angiography (CTA) with a 
Fisher Grade > 1.  All patients also had a blood or CSF sample to obtain a deoxyribonucleic acid 
(DNA) sample for analysis.  Finally, all subjects in the sample were Caucasian.  This was 
because the genotype distributions of the ET-1 SNPs were different between the different races.  
By excluding minorities we were able to prevent false associations in our finding that may have 
been caused by these distribution differences.   
Patients were excluded from the study if they had a preexisting neurological disorder. 
Patients were admitted to the Neurovascular intensive care unit (NV-ICU) at the University of 
Pittsburgh Medical Center (UPMC) from September 2000 to April 2006.  All patients received 
standard nursing and medical care in the NV-ICU including triple-H therapy (hypertension, 
hypervolemia, and hemodilution), nimodipine, and early surgical or endovascular intervention. 
This sample of 250 subjects will be used to describe the distribution of ET-1 polymorphisms in 
the aSAH population.   
A subset of 96 subjects will be used to investigate the relationships between ET-1 
polymorphisms and outcomes following aSAH.  These subjects had the same inclusion and 
exclusion criteria mentioned above.  In addition these subjects had a cerebral angiogram to rule 
out CV during their first 14 days after aneurysm rupture and global functional outcomes 
measured at 3 months and 6 months after aneurysm rupture.   
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Finally, to assess the relationship between ET-1 CSF levels, ET-1 polymorphisms, and 
CV a subset of 32 subjects will be investigated.  These 36 subjects had external ventricular drain 
catheters (EVDs) present as a part of their treatment for aSAH and had a cerebral angiogram to 
rule out CV during the first 14 days after admission.  All previously defined exclusion and 
inclusion criteria applied to this subset of patients. 
Demographic information 
Age in years, race, sex, Fisher grade and Hunt and Hess grade were extrapolated from the 
medical record.  Fisher grade and Hunt and Hess grade were assigned by the admitting 
neurosurgeon. 
Cerebral Vasospasm 
Cerebral vasospasm was verified by visualization of narrowing of cerebral vessels as 
documented on cerebral angiography.  Cerebral angiography was conducted in the event of a 
neurological deterioration.  The angiographic studies were interpreted and graded by neuro-
radiologists and neurosurgeons at UPMC for evidence and degree of vasospasm. The degree of 
vasospasm was represented as the percentage of narrowing in the cerebral vessels as follows: 0 
to 25% narrowing was coded as CV negative while >25% narrowing was coded as CV positive.   
Global Functional Outcomes 
These scores were collected at 3 months and 6 months after aneurysm rupture. The GOS, a 
clinical observation scale, categorizes functional outcomes into five levels ranging from 1 to 5 
with 1 indicating death and 5 indicating good recovery (Jennett, 1976).  Inter-rater reliability has 
been reported from 68 – 95% with kappa values from 0.62 to 0.79 (Gennarelli, Spielman, 
Langfitt, Gildenberg, Harrington, Jane, Marshall, Miller, & Pitts, 1982) and correlates well with 
severity of illness.  The GOS has wide acceptance and established validity (Jennett & Bond, 
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1975; Maas, Braakman, Schouten, Minderhoud, & van Zomeren, 1983).  Inter-rater reliability is 
within the acceptable range when there is adherence to assessment guidelines, administration of a 
structured interview, and training of examiners (Wilson, Pettigrew, & Teasdale, 1998).  The 
Modified Rankin Scale is a measure of functional recovery and incorporates mental and physical 
adaptations to the neurological deficits following a neurological injury.  It is easy to use and has 
been widely adopted for use in stroke trials. The MRS score ranges from 0 (no symptoms at all) 
to 6 (death).  Inter-observer kappa were 0.56 and weighted kappa were 0.91 (Sulter, Steen, & De 
Keyser, 1999).  Both global functional outcome scores were collected by a trained 
neuropsychological technician who was blinded to genotype. 
DNA Specimens   
Subjects had 10cc of whole blood drawn.  The tube of blood was delivered to the genetics 
laboratory with no personal identifiers, labeled only with the study participant’s identification 
number, date, and time of sample collection.  The sample was logged in and centrifuged, the 
white cells removed, and DNA extracted from the white cells using a simple salting out 
procedure (Miller, Dykes, & Polesky, 1988).  All DNA was stored in 1X TE buffer at 4°C until 
genotyping was performed.   
Genotyping  
Genotyping was performed as follows: An ABI Prism® 7000 Sequence Detection System was 
used to conduct allele discrimination assays using TaqMan® allele discrimination assays.  This 
is a highly automated, high throughput genotyping method for SNPs.  Primers flank each 
polymorphism and polymerase chain reaction (PCR) is conducted using subject DNA.  The main 
difference between TaqMan® PCR and traditional PCR is the use of a probe that is labeled with 
a reporter and a quencher dye that recognizes a specific allele of a SNP.  Each allele of a SNP 
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has its own probe with its own reporter dye.  If the subject’s DNA is homozygous for one allele 
of the SNP, only the probe for that allele will hybridize and only the reporter dye for that allele 
will be liberated and measured by the ABI Prism® 7000 Sequence Detection System.  A 
heterozygote had both probes hybridize and both reporter dyes measured.  Using this method, 
each SNP was genotyped accurately and quickly. All SNPs in this study were available as 
TaqMan® assays available through ABI.  Tagging SNPs of ET-1 and Lys198Asn were classified 
into one of three genotypes.  These genotypes were homozygous for the wild type, homozygous 
for the variant, or heterozygous.  For the final analysis that assesses the relationship between ET-
1 CSF levels, ET-1 polymorphisms, and CV the genotypes were categorized as variant positive 
or variant negative.  Variant positive genotypes were either homozygous variant or heterozygous.  
Variant negative genotypes were homozygous wild type.   
Cerebrospinal Fluid Specimens for ET-1 Level Evaluation 
Cerebrospinal fluid specimens were obtained twice daily from indwelling external ventricular 
devices (EVDs) or lumbar drains (LDs).  To obtain samples, specimens were collected from the 
drainage catheter at the site closest to the patient and then immediately frozen in cryogenic vials 
to –20oC. At the end of 14 days when all collections were completed the specimens were stored 
in –80oC freezers until analysis.   The total CSF volume drained since the last sample collection 
was also recorded at the time of sample collection.   
Measurement of ET-1 
The CSF samples were assayed for ET-1 using the ELISA kit QuantiGlo® Human Endothelin-1 
from R&D Systems.  This assay employs the quantitative sandwich enzyme immunoassay 
technique with chemiluminesent detection.  Chemiluminescent kits were required in this analysis 
because typical colorimetric kits lacked sufficient sensitivity to allow for CSF ET-1 
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concentration measurements.  The standard curve was modified from the R&D recommendations 
to include 0.195, 0.39, 0.78, 1.56, 3.13, 6.25, & 12.5 pg/ml standards.  Precision and accuracy of 
the modified standard curve range was evaluated with intra-assay and inter-assay coefficients of 
variation.  The intra-assay coefficients of variation were 14.1% 14.0% and 13.2% for the 
standards of 0.195, 1.56, and 12.5 pg/ml respectively.  The inter-assay coefficients of variation 
were 9.57%, 12.67%, and 9.0% for the standards of 0.195, 1.56, and 12.5 pg/ml respectively.  
This range of standards was used to cover the range of concentrations observed in the CSF of 
SAH patients.  A microplate luminometer (Model # 1420-012 Victor-Wallac, Finland) was used 
to measure the intensity of the light emitted.   
Statistical Analysis 
SPSS version 16.0 was used for all analyses.  Values are presented in the tables and text as mean 
± SD.  Differences in demographics based on CV status, outcome scores, and genotypes were 
investigated using chi-square or fisher analysis for categorical variables, and independent t-test 
for continuous variables.   
Binary logistic regression was used to evaluate the relationship between genotype and 
CV controlling for age and Fisher grade.  A significant difference was defined as a p ≤ 0.05.  
Outcomes at 3 months and at 6 months were evaluated using multinomial logistic regression.  In 
this analysis age, Hunt and Hess grade, and CV status were controlled for in the model.  A 
significant difference was defined as a p ≤ 0.05.   
For the evaluation of the relationship of ET-1 CSF levels and ET-1 genotypes on CV 
following aSAH the ET-1 protein elimination rate was calculated in a similar manner to Shore et 
al (2004), the formula is as follows: 
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Elimination Rate (pg/hr) = Concentration of Sample (pg/ml) X CSF Drainage (ml) 
                            Time Period (hr) 
 
This calculation allows the researcher to control for the CSF volume that was drained 
from the CSF catheters.  The average elimination rate was calculated for 24 hours, 48 hours, 72 
hours before angiography, and 72 hours after angiography.  The subjects were divided into CV 
positive and CV negative groups as previously defined.    Binary logistic regression was used to 
evaluate the association between average ET-1 elimination rates at 72 hours before, 48 hours 
before, 24 hours before and 72 hours after angiography and the outcome measure of CV 
controlling for age and Fisher grade at the first step and individual polymorphism genotypes 
controlled for at the second step.  A significant difference was defined as a p ≤ 0.05.   
4.3 RESULTS 
There were 250 subjects with genotype data and demographic information.  These subjects were 
predominantly female (n=174; 69.9%) and all were Caucasian.  The mean subject age was 53.84 
± 11.2 years old.  All Et-1 genotypes were in Hardy Weinberg equilibrium.  There were no 
significant differences in genotype distribution of the ET-1 SNPs for this sample when compared 
to the general population.     
There were 96 subjects with genotype data, demographic information, and angiographic 
measurement of vasospasm, 3 months and 6 month global functional outcome scores.  The 
subjects were predominantly female (n=73; 76%) and all subjects were Caucasian.  The mean 
subject age was 55.60 ±10.28 years old.  Demographic information in relationship to vasospasm 
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is presented in Table 3.    There were no significant differences in demographics between the two 
groups.  There were also no differences in demographics when comparing genotype groups 
within the polymorphisms.   
 
Table 3: Demographics of Subjects with Outcomes Measurement Categorized by CV (n=96) 
     CV Negative  CV Positive  p value 
Sex   Male   16 (69.6%)  7 (30.4%)  0.100 
  Female  36 (49.3%)  37 (50.7%) 
Age  Mean (SD)  56.2 (9.6)  54.9 (11.1)  0.545 
Hunt &Hess  1   7 (7.3%)  4 (4.2%)  0.480   
Grade  2   20 (20.8%)  11 (11.5%)   
  3   16 (16.7%)  16 (16.7%) 
  4   6 (6.3%)  9 (9.4%) 
  5   3 (3.1%)  4 (4.2%) 
Fisher  1   0 (0%)   0 (0%)   0.406 
Grade  2   14 (14.6%)  7 (7.3%) 
  3   28 (29.2%)  26 (27.1%) 
  4   10 (10.4%)  11 (11.5%) 
 
Of the 9 ET-1 SNPs investigated 1 ET-1 SNPs had genotypes that were predictive of CV 
when controlling for age and Fisher grade (Table 4).   This tagging SNP was rs2070699 
(p=0.012, Table 5).  The odds ratio of the heterozygous genotype compared to the homozygous 
wild-type genotype was 2.970 with a 95% confidence interval of 0.998 to 8.836.  The odds ratio 
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for the homozygous variant genotype compared to the homozygous wild-type genotype was 
8.356 with a 95% confidence interval of 2.032 to 34.371.  See Figure 4 for distribution of 
rs2070699’s genotypes by CV status.  The ET-1 SNP’s genotypes were not a significant 
predictor of long term outcomes when controlling for age, Hunt and Hess grade, and CV.   
 
Table 4: Logistic Regression Analysis of Individual SNPs of the ET-1 Gene controlling for 
Fisher Grade and Age (* indicates significance at p<0.05) 
SNP Wald X2 df Sig 
rs1800541 0.701 2 0.704 
rs3087459 0.527 2 0.768 
rs2070699 8.782 2 0.012* 
rs1476046 1.472 2 0.479 
rs5369 0.546 2 0.761 
rs1626492 0.632 2 0.729 
rs6912834 1.786 2 0.409 
rs2071943 1.360 2 0.507 
rs5370 0.781 2 0.677 
 
 
 
 
 
 
Table 5: Logistic Regression Analysis of rs2070699. 
Predictor     Odds Ratio   Confidence Interval
Constant     0.298      
Age      0.989    0.946 to 1.034 
Fisher Grade 2    1.0 
Fisher Grade 3    2.119    0.671 to 6.692 
Fisher Grade 4    2.855    0.735 to 11.094 
RS2070699 Homozygous Wild Type  1.0 
Heterozygous      2.970    0.998 to 8.836 
Homozygous Variant    8.356    2.032 to 34.371 
 
______________________________________________________________________________ 
 
Test     X2   df   p 
 
______________________________________________________________________________ 
Goodness-of-fit test    
Hosmer & Lemeshow   3.035   8   0.932 
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Figure 4: Percentage of subjects with CV categorized by genotype of rs2070699. 
 
There were 32 subjects with ET-1 CSF measurements, demographic information, 
genotype information and angiographic data available.  These subjects were predominantly 
female (n=20; 62.5%) and all were Caucasian (n=32; 100 %).  The average subject age was 
56.34 ± 10.64 years old with a median age of 56.5 years old.  There were no significant 
differences in demographics between the CV positive and CV negative groups.   
The average ET-1 elimination rate for the 24 hours before angiography for the CV 
negative and positive groups (3.80 ±2.82 pg/hr versus 6.72±5.71 pg/hr) or for the 48 hours 
before angiography for the CV negative and positive groups (3.72±2.53 pg/hr versus 7.15±6.75 
pg/hr) were not significant predictors.  The average ET-1 elimination rate for the 72 hours before 
angiography was 4.02±2.53 pg/hr for the CV negative group and 9.35±7.28 pg/hr for the CV 
positive group (Figure 5).  The 72 hour ET-1 elimination rate was a significant predictor in this 
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model when controlling for age and Fisher grade (p=0.022), which supports findings from an 
earlier paper (Gallek et al., 2008).  The average ET-1 elimination rate 72 hours after angiography 
showed no difference between the CV negative group (3.80±2.33 pg/hr) and the CV positive 
group (5.22±4.30 pg/hr).  However, when ET-1 levels and ET-1 genotypes are included in the 
model, there is no significant interaction between the two variables.   
 
 
 
Figure 5: Average ET-1 elimination rate (pg/hr) 72 hours before angiographic measurement of 
vasospasm.  The horizontal bar indicates the mean of each group. 
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4.4 DISCUSSION 
The distribution of the genotypes for the sample of 250 Caucasian subjects was not significantly 
different when compared to the HAP-MAP database of the general Caucasian population.  From 
this finding we conclude that ET-1 genetic variation does not play a role in aneurysm formation, 
aneurysm development, or rupture.  If ET-1 was involved with aneurysm formation or rupture, 
we would have expected the genotype distribution to be different in this diseased sample when 
compared to the general population.   
The genotype distribution of the subset of 96 subjects with angiographic and global 
functional outcomes also has a similar distribution when compared to the general population.  
The functional SNP (Lys198Asn) had no association with CV after aSAH.  Therefore, the 
difference in vascular response to ET-1 as reported by Iglarz et al (2002) does not appear to play 
a part in the etiology of CV.  This difference in vascular response reported previously may not 
play a role in CV due to the aSAH disease process and other influences following aSAH.  The 
tagging SNP whose genotypes were associated with CV was rs2070699.  The presence of the 
variant allele of this SNP was associated with an increased occurrence of CV in a dose response 
manner.  A subject with a heterozygous genotype was 2.97 times more likely to have CV when 
compared to a subject with a homozygous wild type genotype.  While a subject with the 
homozygous variant genotype was at the highest risk of have CV.  These subjects were 8.36 
times more likely to have CV when compared to a subject with the homozygous variant 
genotype.    These genotype associations support that ET-1 plays a role in the development of 
CV after aSAH and that the gene product associated with the variant allele of the rs2070699 SNP 
may lead to more potent vasoconstriction. 
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While the SNP rs2070699 is within an intron of the ET-1 gene and has no direct effect on 
the mature protein, the region of the ET-1 gene that it represents has SNPs that may affect the 
mature ET-1 protein.  Based on the website http://hapmap.org/ the associated block of base pairs 
is located on Chromosome 6: position 12400758 to 12403973.  Within this block of genetic 
information is the SNP rs35104761 which causes a deletion of a base pair and a frameshift 
mutation.  This frameshift mutation may significantly change amino acids of the mature protein 
or may cause the translation of the protein to prematurely stop.  The SNP rs35104761 is a 
possible candidate for the differences in occurrence of vasospasm accounted for by the SNP 
rs2070699. 
While there were no significant associations found between ET-1 SNPs and global 
functional outcomes at 3 and 6 months, these findings are still of interest.  Long term recovery 
from aSAH is very complex and multifactorial.  There are numerous genes that are involved in 
recovery and cell repair.  Our findings lead to the conclusion that ET-1 is most likely not a major 
direct contributor to long term recovery after aSAH.  However, ET-1 mediates CV which in the 
long run will affect long term outcomes. 
While ET-1 average elimination rate at 72 hours before angiography is a significant 
predictor in our model (p=0.022) with higher ET-1 elimination rates being predictive of CV.  
There appears to be no interaction between the ET-1 elimination rate and ET-1 genotype in this 
model.  This may be due to the small number of subjects within this sample.  By having an 
underpowered test we were unable to elucidate the association between the ET-1 genotypes and 
the ET-1 levels.   
Limitations to this study include the lack of minorities in our sample.  Minority subjects 
are not presented in this study because the size of the minority sample that is available to us 
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would make it a very under powered analysis.  The minority population is small in the Pittsburgh 
region and because of that our minority sample is less than 10% of the overall aSAH population.  
In the future as we are able to recruit a larger number of minorities we will be able to report the 
genetic characteristics of the ET-1 SNPs for this aSAH population.   
The second limitation is that we were able to only include patients that had a cerebral 
angiography as a measure of the presence or absence of CV.  The majority of this study’s 
patients had a clinical need for an angiography (i.e. change in level of consciousness).  By 
including patients that have a need for angiography the sample is skewed towards subjects that 
are in a more critical state.  Those patients that were in a less critical state may have differences 
in their genotype distributions when compared to the more critical patients.  These differences in 
genotype distribution may account for differences in the overall state of the patients.  In addition 
we were only able to include patients that had follow up visits with the neuropsychological 
technician.  In the overall study population 21% of patients were not available for 3 month 
follow up while 24% of patients were not available for 6 months follow up.  Therefore, any 
subjects that were unable or unwilling to participate in the follow up testing would not be 
included in this sample.   
The third limitation of this study was the relatively small number of patients in our 
sample that investigated the relationships between ET-1 SNP’s, ET-1 levels and CV.  Our 
sample size is limited by two major factors.  One, our patients need to have an EVD or LD to 
collect the ET-1 levels.  Not all patients clinically have a need for an EVD or LD, therefore that 
portion of the population was not included in this study.  In addition our sample size is limited by 
follow up angiography.  As stated above, the majority of angiograms are performed on patients 
that have a clinical neurological deterioration.  Patients with clinical neurologic deterioration and 
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EVD’s are more critically ill.  As such our findings may not be representative of the general 
aSAH population.  Future work should include a larger sample size to give more power to such a 
study.  We were however able to identify significant differences in ET-1 elimination 72 hours 
before angiographic cerebral vasospasm suggesting that the effect size was large enough to 
accommodate the small sample size.   
In summary, we found that the variant allele of tagging SNP RS2070699 was associated 
with an increased incidence of CV following aSAH.  This suggests that ET-1 does play a role in 
the development of CV after aSAH.  Further investigation needs to continue to find the 
functional SNP that is within the region of the ET-1 gene represented by that tagging SNP. 
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APPENDIX A 
 
GLASGOW OUTCOME SCORE 
___1. Dead 
 
___2. Vegetative State 
Unable to interact with environment; unresponsive. Patients who show no evidence of 
meaningful responsiveness. Patients who obey even simple commands, or who utter any words, 
are assigned to the better category of severe disability. Vegetative patients breathe 
spontaneously, have periods of spontaneous eye-opening when they may follow moving objects 
with their eyes, show reflex responses in their limbs (to postural or painful stimuli), and they 
may swallow food placed in their mouths. This non-sentient state must be distinguished from 
other conditions of wakeful, reduced responsiveness--such as the locked-in syndrome, akinetic 
mutism and total global aphasia.   
 
___3.  Severe Disability 
Able to follow commands/ unable to live independently.  This indicates that a patient is 
conscious but needs the assistance of another person for some activities of daily living every day. 
This may range from continuous total dependency (for feeding and washing) to the need for 
assistance with only one activity--such as dressing, getting out of bed or moving about the house, 
or going outside to a shop. Often dependency is due to a combination of physical and mental 
disability--because when physical disability is severe after head injury there is almost always 
considerable mental deficit. The patient cannot be left overnight because they would be unable to 
plan their meals or to deal with callers, or any domestic crisis which might arise. The severely 
disabled are described by the phrase "conscious but dependent."   
 
___4.  Moderate Disability 
Able to live independently; unable to return to work or school.  These patients may be 
summarized as "independent but disabled," but it is perhaps the least easily described category of 
survivor. Such a patient is able to look after himself at home, to get out and about to the shops 
and to travel by public transport. However, some previous activities, either at work or in social 
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life, are now no longer possible by reason of either physical or mental deficit. Some patients in 
this category are able to return to certain kinds of work, even to their own job, if this happens not 
to involve a high level of performance in the area of their major deficit.   
 
___5.  Good Recovery 
Able to return to work or school.  This indicates the capacity to resume normal occupational and 
social activities, although there may be minor physical or mental deficits.  However, for various 
reasons, the patient may not have resumed all his previous activities, and in particular may not be 
working.   
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APPENDIX B 
MODIFIED RANKIN SCORE 
SCORE DESCRIPTION  
 
0  No symptoms at all  
 
1 No significant disability despite symptoms; able to carry out all usual
 duties and activities  
 
2  Slight disability; unable to carry out all previous activities, but able  
to look after own affairs without assistance  
 
3  Moderate disability; requiring some help, but able to walk without
 assistance  
 
4 Moderately severe disability; unable to walk without assistance and unable 
to attend to own bodily needs without assistance  
 
5 Severe disability; bedridden, incontinent and requiring constant nursing 
care and attention  
 
6  Dead 
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APPENDIX C 
THE HUNT AND HESS GRADING SCALE 
Hunt and Hess Classification  
 
 Grade 0- Unruptured Aneurysm 
 
 Grade 1- Asymptomatic or mild headache with slight nuchal rigidity. 
 
 Grade 2- Cranial nerve palsy, moderate to severe headache, nuchal rigidity 
 
 Grade 3- Mild focal deficit, lethargy or confusion 
 
 Grade 4- Stupor, moderate to severe hemiparesis 
 
 Grade 5- Deep coma, decerebrate rigidity, moribund appearance 
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APPENDIX D 
THE FISHER GRADING SCALE 
Fisher Grading Scale   
 
 Grade 1- No blood detected on CT scan 
 
 Grade 2- Diffuse deposition or thin layer with all vertical layers of blood less than 1 
mm thick 
  
 Grade 3- Localized clots and/or vertical layers of blood 1mm or greater in thickness 
 
Grade 4- Intracerebral or intraventricular clot with diffuse or no subarachnoid 
hemorrhage 
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APPENDIX E 
IRB APPROVAL LETTER 
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